Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
02/2009 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions February patent applications/inventions, industry category 02/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/26/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090054300 - Compositions and methods for the treatment of systemic lupus erythematosis: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090054301 - Hypoallergenic composition: This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal (including pet) consumption, and particularly hypoallergenic compositions, and more particularly semi-solid hypoallergenic compositions and hypoallergenic compositions that comprise a hydrolysate. This invention also is directed generally to methods for using such compositions. This invention is... Agent: Colgate-palmolive Company

20090054302 - Methods and preparations for curing clinically ill patients: This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090054303 - Crystal forms of saxagliptin and processes for preparing same: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and... Agent: Louis J. Wille Bristol-myers Squibb Company

20090054304 - Heterocyclic modulators of tgr5 for treatment of disease: The present invention relates to compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090054305 - Mixtures of amylin and insulin: The present invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide, and a meal-related insulin peptide, and to the use of such compositions for treatment of e.g. hyperglycemia.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090054308 - Methods and compositions for treating pulmonary hypertension and related diseases and disorders: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and at least one other active pharmaceutical ingredient to patient in need thereof. Pharmaceutical formulations are also disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20090054306 - Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090054307 - Prophylactic and therapeutic agents and uses therefor: Treatment, detection and monitoring of disease of the nervous system, especially trauma or hypoxia, in particular in the central nervous system and the eye by up-regulation or increasing levels of Ndfip1 (also known as Nedd4-WW Domain Binding Protein 5 or N4WBP5). Prophylaxis of such conditions in pre-term infants, coronary artery... Agent: Knobbe Martens Olson & Bear LLP

20090054310 - Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds: The invention provides methods for predicting toxicity related to calcineurin inhibition therapy by measuring the peak concentration of drug and the trough concentration of the drug, calculating a peak-trough fluctuation, and comparing this peak-trough fluctuation to known values to predict if the patient will exhibit calcineurin-inhibition therapy-related toxicity. The invention... Agent: Fish & Richardson P.C.

20090054311 - Novel cyclosporin analog formulations: The present invention relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects... Agent: Fish & Richardson P.C.

20090054309 - Peptidic vasopressin receptor agonists: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by... Agent: Foley And Lardner LLP Suite 500

20090054312 - Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases: Methods are provided for screening for SMIPs (small molecule inhibitors of p27 depletion). The SMIPs thus identified are useful for treating cancers and other proliferative diseases.... Agent: Biotechnology Law Group C/o Portfolioip

20090054316 - Agent for control of function of antigen-presenting cell: The present invention provides an agent capable of controlling the function of antigen-presenting cell. The present invention provides an agent for controlling the function of antigen-presenting cell, comprising a substance capable of controlling an intracellular zinc ion concentration, particularly, a zinc ion, a zinc ion chelator, a substance for regulating... Agent: Leydig Voit & Mayer, Ltd

20090054335 - Axmi-028 and axmi-029, a family of novel delta-endotoxin genes and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Alston & Bird LLP

20090054336 - Binding agent: Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents.... Agent: Crowell & Moring LLP Intellectual Property Group

20090054334 - Combinatorial improvement of bifunctional drug properties: A method is provided for improving at least one pharmacokinetic property and maintaining or improving affinity of a therapeutic upon administration to a host. In the method, one administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the therapeutic or an... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090054314 - Combined use of dpp-iv inhibitors and gastrin compounds: The invention relates to compositions, conjugates, and methods for the prevention and/or treatment of a condition and/or disease comprising a therapeutically effective amount of a DPP-IV inhibitor and a gastrin compound. The combination of a DPP-IV inhibitor and a gastrin compound provides beneficial effects, in particular sustained beneficial effects, in... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090054329 - Composition with docosapentaenoic acid: This invention concerns a method for stimulating barrier integrity in a subject by administering to a subject a composition comprising docosapentaenoic acid (22:5 n3; DPA). Also the invention concerns a composition comprising DPA and eicosapentaenoic acid (EPA).... Agent: Foley And Lardner LLP Suite 500

20090054325 - Compositions and methods for suppressing axonal growth inhibition: The invention provides compositions and methods for interfering with Nogo-receptor mediated signaling and mediating axonal growth. The invention also provides methods for treating central nervous system diseases, disorders or injuries.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090054315 - Counteracting drug-induced obesity using glp-1 agonists: The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090054326 - Formulations for enhanced mucosal delivery of pyy: Pharmaceutical formulations are described for enhancing mucosal delivery of peptide YY (PYY) to a mammal. A PYY dosage form is described that is suitable for multi-use administration. The PYY dosage form comprises a bottle containing an aqueous pharmaceutical formulation and an actuator effective intranasal administration of the formulation. The formulation... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20090054331 - High temperature stable peptide formulation: A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a... Agent: Bozicevic, Field & Francis LLP

20090054318 - Immunopotentiating agent: Satisfactory effects have not always been attained by immunotherapy having been tried, and reliance upon direct attack on cells by anticancer agents, radiation, etc has been inevitable. The present invention intends to provide a therapeutic method that ensures less side effects but higher efficacy than in conventional therapeutic methods through... Agent: Birch Stewart Kolasch & Birch

20090054319 - Methods and compositions for the treatment of hypertension and gastrointestinal disorders: The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD),... Agent: Fish & Richardson PC

20090054341 - Methods of treatment using exendin peptides or glp-1 peptides: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia,... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090054337 - Natriuretic polypeptides: This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal.... Agent: Fish & Richardson P.C.

20090054339 - Novel cellular factor-containing solution compositions: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.... Agent: Linda O. Palladino

20090054330 - Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection: The present invention provides a method of blocking xenograft rejection in a patient in need of such treatment by administering to said patient a virally-encoded complement control protein, referred to as the inflammation modulatory protein (IMP). The present invention further provides pharmaceutical compositions for the prevention or treatment of xenograft... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090054333 - Peptide inhibitors of cyclin-dependent kinase activity and uses thereof: Novel polypeptides or derivatives comprising cdk2 binding site are disclosed. The novel polypeptides or derivatives have growth suppressive activity. Nucleic acids encoding those polypeptides are also disclosed. The polypeptides identified herein are also useful in methods for treating or preventing cancer. The treatment methods comprise administration of the polypeptide to... Agent: Reed Smith LLP

20090054322 - Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions: An isolated polynucleotide is provided, comprising a nucleic acid sequence encoding a soluble polypeptide which comprises an amino acid sequence of an N-terminus domain of CXCR4 and devoid of a CXCR4 extracellular domain selected from the group consisting of ECL1, ECL2 and ECL3, the soluble polypeptide being capable of binding... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090054321 - Polypeptides and use thereof: An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A... Agent: Jacobson Holman PLLC

20090054317 - Polyvalent inhibitors of pathogens: The present invention provides polyvalent host cell receptor-directed pathogen inhibitors and methods for designing and using such polyvalent inhibitors. Polyvalent inhibitors of the invention comprise a biocompatible scaffold having attached thereto a plurality of ligands, e.g. peptides, capable of binding a host cell receptor or portion thereof of a pathogen... Agent: Elmore Patent Law Group, PC

20090054328 - Reagents and methods for modulating gene expression related to hypertension: This invention relates to gene expression and proliferation in eukaryotic, preferably mammalian and most preferably human cells. The invention specifically relates to hypertension associated with proliferation and contractility of vascular smooth muscle cells.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090054323 - Specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Larry S. Millstein Holland & Knight LLP

20090054338 - Synergisms between repartitioning and immunomodulating compounds: Combination therapies of adrenergic beta-receptor agonists and beta-glucans are described.... Agent: Nields & Lemack

20090054327 - Tat-utrophin as a protein therapy for dystrophinopathies: Disclosed is a fusion protein including a full-length TAT-utrophin or an anti-dystrophinopathic fragment thereof, a method of treating dystrophinopathies (including Duchenne muscular dystrophy) using the fusion protein, a pharmaceutical composition for treating treating dystrophinopathies in mammals comprising the fusion protein, and nucleic acid constructs for expressing the fusion protein.... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20090054332 - Thombopoietin peptide conjugates: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide,... Agent: Lowrie, Lando & Anastasi, LLP

20090054324 - Transcriptional regulation of high affitnity ige receptor gamma-chain: Transcriptional regulatory regions and transcriptional regulatory factors for the human high affinity IgE receptor (FcεRI) γ-chain gene are specified and are targets for the development of transcriptional regulatory agents for the FcεRI γ-chain gene. The following are provided: DNA comprising the full length or a portion of the base sequence... Agent: Morgan Lewis & Bockius LLP

20090054340 - Use of heat-shock protein 27 for cardiovascular disease prevention and treatment: A method of preventing or treating cardiovascular disease is provided. The method comprises administering heat shock protein 27 (HSP27), a co-factor, variant or analogue thereof. The cardiovascular disease can include atherosclerosis. A pharmaceutical composition comprising HSP27 for use in the prevention or treatment of cardiovascular disease is also provided.... Agent: Borden Ladner Gervais LLP Anne Kinsman

20090054320 - Vesiculins: The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and... Agent: Greenlee Winner And Sullivan P C

20090054342 - Bioactive peptides and method of using same: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090054343 - Methods of therapy using pharmaceutical composition for thrombin peptide derivatives: Disclosed are pharmaceutical compositions comprising a thrombin peptide derivatives and a chelating agent and/or a pharmaceutically acceptable thiol-containing compound. The pharmaceutical compositions optionally further comprise an antioxidant. Also, disclosed are methods for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment. The methods comprise the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090054344 - Anti-angiogenic proteins and fragments and methods of use thereof: Proteins with anti-angiogenic properties are disclosed, and fragments thereof, and methods of using those proteins and fragments to inhibit or promote angiogenesis.... Agent: Nixon Peabody, LLP

20090054348 - Bi-dentate compounds as kinase inhibitors: wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide mimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A... Agent: Dla Piper LLP (us)

20090054346 - Elastin production-enhancing agents: An objective of the present invention is to provide novel useful elastin production-enhancing agents that have a remarkable ability to enhance elastin production. The present invention provides elastin production-enhancing agents that include at least one component selected from the group consisting of the peptide Leu-Glu-His-Ala (formula I; SEQ ID NO:1),... Agent: Townsend And Townsend And Crew, LLP

20090054347 - Kinin b1 receptor peptide agonists and uses thereof: The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B1 receptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery... Agent: Bereskin And Parr

20090054345 - Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity: Templates-fixed β-hairpin peptidomimetics of the general formulae (I), wherein Z is a chain of 11α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above... Agent: Hoffmann & Baron, LLP

20090054349 - Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same: The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin β-4 (Tβ4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human Tβ4 and its biological activity is almost identical to natural-occurring Tβ4. In addition, the... Agent: The Nath Law Group

20090054350 - Process for the sterile concentration of collagen preparations, and collagen preparations obtained: The invention relates to a process for the preparation of sterile collagen, especially injectable collagen, comprising the steps of preparing a purified acidic collagen solution, filtering that solution through a filter or a sterile membrane, precipitating the filtered solution in the form of a suspension, and concentrating the collagen suspension,... Agent: Stites & Harbison PLLC

20090054351 - Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases: The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or... Agent: Fulbright & Jaworski L.L.P.

20090054352 - Benzene derivative or salt thereof: Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have... Agent: Fitzpatrick Cella Harper & Scinto

20090054353 - Mannosyl-1 phosphates, preparation method and therapeutic use, in particular against the cdg-ia syndrome: a

20090054354 - Drug and food or drink for improving pancreatic functions: Compounds having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol are used as an active ingredient of a drug and food or drink for improving pancreatic functions.... Agent: Knobbe Martens Olson & Bear LLP

20090054355 - Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives: m

20090054356 - 1-substituted-7-(b-d-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same: wherein R1 represents a halogen atom or the like; n represents j an integer number from 0 to 3; R2 represents a hydrogen atom or the like; X represents a carbon atom which a hydrogen atom or the like binds to, or a nitrogen atom; Q represents an alkylene group... Agent: Sughrue Mion, PLLC

20090054357 - Macrolide compounds endowed with antiinflammatory activity: Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090054359 - Compositions and their uses directed to diacylglycerol acyltransferase 1: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a... Agent: Mcdermott Will & Emery

20090054358 - Flt3 inhibitors for immune suppression: New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic... Agent: Edwards Angell Palmer & Dodge LLP

20090054360 - Method and composition for treating allergic diseases: A method and composition for treating allergic diseases and/or airway inflammation including pollinosis, bronchial asthma, allergic rhinitis, atopic dermatitis and anaphylactic shock with the administration to a subject an amount of an anti-infectious agent such as ribavirin and optionally combined with an anti-inflammatory agent selected from inhaled steroids, leukotriene receptor... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090054362 - Compounds: The present invention provides novel aptamer derivatives which are useful in binding to and neutralising viruses. Pharmaceutical formulations comprising the aptamers and the use of the aptamers in screening for useful compounds are also provided.... Agent: Brooks Kushman P.C.

20090054363 - Genetic markers and methods for detecting and treating cancers: The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method... Agent: Birch Stewart Kolasch & Birch

20090054364 - Methods and compositions for delivery of pharmaceutical agents: Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the... Agent: Morrison & Foerster LLP

20090054367 - Mycobacterial antigens expressed under low oxygen tension: A method is provided for identifying mycobacterial genes that are induced or up-regulated under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37° C. when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37° C.... Agent: Evan Law Group LLC

20090054361 - Pot1 alternative splicing variants: The present invention provides methods an compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk... Agent: Edwards Angell Palmer & Dodge LLP

20090054366 - Rnai mediated knockdown of numa for cancer therapy: This invention relates to the use of short interfering nucleic acid molecules (siRNA) to inhibit Nuclear Mitotic Apparatus Protein (NuMA) gene expression and their use in treatment of disease, including cancer.... Agent: Foley And Lardner LLP Suite 500

20090054365 - Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization: RNA interference is provided for inhibition of aquaporin 1 (AQP1) to treat conditions associated with neovascularization.... Agent: Alcon

20090054368 - Substituted gemini surfactant compounds: The compositions, systems, and methods relate to substituted and asymmetric gemini surfactants for use in delivering biologically active agents, such as nucleic acids, to a subject. The described compositions, systems, and methods are useful for gene therapy.... Agent: King & Spalding LLP

20090054369 - Pharmaceutical compositions of silicon-containing substituted adenosine nucleoside amide analogs: Novel compositions of silicon-containing anti-metabolite compounds, their preparation and use in methods for treating cancer are described. The silyl group confers lipophilicity that can enhance the penetration of the compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The... Agent: Duane Morris LLP - ChicagoIPDepartment

20090054370 - Pyrimidines, such as uridine, in treatments for patients with bipolar disorder: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.... Agent: Clark & Elbing LLP

20090054372 - Combination therapy for weight loss: The present invention is directed to methods and kits for achieving or maintaining weight loss. These kits and methods can include administering a pharmaceutical composition comprising phentermine, topiramate and a B vitamin to a subject in need thereof.... Agent: Venable LLP

20090054371 - Folic acid-, vitamin b6- and vitamin b12-containing agents and the use thereof: The invention relates to agents containing a folic acid, vitamin B6 and vitamin B12 and to the use thereof in hyperhomocystenemia for controlling homocysteine levels. The inventive agents are particularly suitable for preventive and acute treatment of vascular diseases of pregnant women and neurodegenerative diseases and are particularly advantageous in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090054373 - Chitin derivatives for hyperlipidemia: The preferred embodiments relate to chitin derivatives for prevention or treatment of hyperlipidemia, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The preferred embodiments are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal.... Agent: Knobbe Martens Olson & Bear LLP

20090054374 - Methods of treating acute exacerbations of chronic obstructive pulmonary disease: The present invention provides methods for treating and preventing acute exacerbations of Chronic Obstructive Pulmonary Disease. The methods particularly comprise administering to a patient have COPD a composition comprising O-desulfated heparin. The administration can be after onset of one or more symptoms indicating an exacerbation of COPD or prior to... Agent: Alston & Bird LLP

20090054375 - Compositions, systems, and/or methods involving chlorine dioxide: Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. When stored, a concentration of the chlorine dioxide in the composition of matter can be retained, with respect to an initial concentration of chlorine dioxide in said composition of matter,... Agent: Michael N. Haynes

20090054313 - Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of lmp-1 and bmp-2: The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics.... Agent: Medtronic Spinal And Biologics Attn: Noreen Johnson -IPLegal Department

20090054376 - Benzofuran derivatives with therapeutic activities: The present invention relates to novel benzofuran compounds, to pharmaceutical compositions that include such compounds, and to methods of use thereof. Certain compounds of the invention share some pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are useful... Agent: Winston & Strawn LLP Patent Department

20090054377 - Compositions and methods for smoking cessation: The invention discloses a method and a composition for smoking cessation or for promoting smoking cessation in individual smokers. The compositions described contain phosphatidic acid as the active ingredient.... Agent: The Nath Law Group

20090054378 - Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines: R1 and R2 each designate an acyl group derived from a saturated or unsaturated, straight- or branched-chain carboxylic acid having from 2 to 18 carbon atoms, which is unsubstituted or bears one to three substituents selected among hydroxyl, dihydroxyphosphoryloxy, alkyl of 2 to 10 carbon atoms, alkoxy of 2 to... Agent: Young & Thompson

20090054379 - 7-pyrollyl 9-aminoacyl tetracycline compounds and methods of use thereof:

20090054380 - Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection: The present invention relates to Mycobacterium avium subspecies paratuberculosis (MAP) as the etiological agent of IBD, including ulcerative colitis and Crohn's disease, as well as Multiple Sclerosis and Alzheimer's Disease. As such, the present invention provides a method for diagnosing Multiple Sclerosis and Alzheimer's Disease by detecting the presence of... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090054382 - Compositions of phosphodiesterase type iv inhibitors: Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods... Agent: Ranbaxy Inc.

20090054381 - Methods for treating respiratory disorders: The invention provides methods for treating respiratory disorders in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one therapeutic agent. The hydralazine compound may... Agent: Wilmerhale/nitromed

20090054383 - Pharmaceutical compositions: Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance,... Agent: Ostrolenk Faber Gerb & Soffen

20090054384 - Airway alkalinization as therapy for airway diseases: The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.... Agent: Williams Mullen

20090054386 - Compositions and methods for inducing bone growth and inhibiting bone loss: Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources, Inc.

20090054385 - Solid inhalation formulations of dehydroepiandrosterone derivatives: Solid pharmaceutical compositions and kits for administration to the lungs comprise a carrier and an agent for the treatment of bronchoconstriction and asthma, wherein the agent comprises a derivative of dehydroepiandrosterone having an SO2H or SO2Na group. The solid formulations can be administered as an aerosol.... Agent: Wilson Sonsini Goodrich & Rosati

20090054387 - Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (e)-oxime (asoprisnil): The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms... Agent: Millen, White, Zelano & Branigan, P.C.

20090054388 - Novel 11 beta-hydroxyandrosta-4-ene-3-ones: e

20090054389 - Topical composition comprising an antibacterial substance: A pharmaceutical composition for topical application comprises a fusidic acid derivative of general formula I as disclosed herein and one or more monoglycerides of a fatty acid. The composition may be used in the treatment of a disease or condition of the skin or mucosa, in particular skin infections.... Agent: Birch Stewart Kolasch & Birch

20090054390 - Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture: This invention relates to methods for providing prognosis of a subjects susceptibility to plaque rupture and compositions for treating plaque rupture and intraplaque hemorrhage. Specifically, the invention is directed to the use of haptoglobin genotyping in determining the susceptibility of a subject to develop intraplaque hemorrhage resulting from plaque rapture... Agent: Pearl Cohen Zedek Latzer, LLP

20090054391 - Biologically active complex: The invention relates to an aqueous solution containing at least one species selected from the group consisting of a 1:1 molar complex of TeO2 with a moiety of formula (A) and ammonium salts thereof: HO—X—OH (A); where X is an optionally substituted divalent saturated hydrocarbon group containing 2-8 carbon atoms... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090054393 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic... Agent: Goodwin Procter LLP Patent Administrator

20090054394 - Polymorphisms in mgst3 are associated with elevated alat levels after ximelagatran treatment: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the MGST3 gene and susceptibility to increased... Agent: Astrazeneca R&d Boston

20090054395 - Sulfonyl amide derivatives for the treatment of abnormal cell growth: wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth... Agent: Pfizer Inc

20090054396 - Substituted thiophenes and uses thereof: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20090054392 - Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system: The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.... Agent: Wyeth Patent Law Group

20090054397 - Pyrazole compounds and pharmaceutical compositions comprising the compound: V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom,... Agent: Birch Stewart Kolasch & Birch

20090054398 - Chemical compounds: The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutically acceptable salt form or in the form of a pharmaceutically acceptable solvate of the... Agent: Astrazeneca R&d Boston

20090054399 - Hiv integrase inhibitors: Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of... Agent: Merck And Co., Inc

20090054400 - New progesterone receptor modulators: The present invention provides new progesterone receptor modulators which are dibenzo[b,f]pyrido[1,2-d]oxazepine-2-amines or dibenzo[b,f]prido[1,2-d]thiazepine-2-amines, and uses thereof.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090054401 - Substituted bicyclic derivatives and use thereof: [In the formula, represents a single bond, or a double bond, Link represents a single bond, or a saturated or unsaturated straight hydrocarbon having 1 or 2 carbon atoms, W represents a single bond, oxygen atom, sulfur atom, N(Rw) etc., Rw represents hydrogen atom, an alkyl group having 1... Agent: Birch Stewart Kolasch & Birch

20090054402 - 7-substituted indole mcl-1 inhibitors: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090054403 - Treatment of post-traumatic stress disorder: Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic... Agent: Fenwick & West LLP

20090054404 - Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain: The present invention relates to the use of a mixture of the enantiomers of a compound of Formula (I) or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45 %... Agent: Novartis Corporate Intellectual Property

20090054405 - Pi3 kinase modulators and methods of use: e

20090054406 - Compositions and methods for modulating endophthalmitis using fluoroquinolones: Compositions for modulating endophthalmitis comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating endophthalmitis comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating post-operative endophthalmitis, post-traumatic endophthalmitis, non-infectious endophthalmitis, panophthalmitis, hematogenous endophthalmitis, or combinations thereof.... Agent: Bausch & Lomb Incorporated

20090054407 - Nitrogen-containing heterocyclic compound: m

20090054411 - 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors: or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and... Agent: Astrazeneca R&d Boston

20090054409 - Imidazo [1,2-a] pyridine having anti-cell-proliferation activity:

20090054408 - Monocyclic anilide spirolactam cgrp receptor antagonists: The present invention is directed to compounds of Formula I: I (where A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CORP is involved, such... Agent: Merck And Co., Inc

20090054410 - Thiadiazole derivatives for the treatment of neurodegenerative diseases: This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for... Agent: Clark & Elbing LLP

20090054412 - Treatment of sleep disorders: A method for treating various types of insomnia is provided using 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt.... Agent: Fitzpatrick Cella Harper & Scinto

20090054416 - 1,4-diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof: m

20090054415 - Combinations, methods and compositions for treating cancer: The invention relates to a combination of BCR-ABL inhibitor, exemplified by ‘N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and/or other BCR/ABL inhibitors, and a stem cell selective cytotoxic, exemplified by (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile, hydrochloride salt, and or other stem cell cytotoxic agents, pharmaceutical compositions of the combination and to methods of using the pharmaceutical compositions in the treatment... Agent: Louis J. Wille Bristol-myers Squibb Company

20090054413 - Novel 5,6-dihydropyrazolo[3,4-e] [l,4]diazepin-4 (ih) -one derivatives for the treatment of asthma and chronic obstructive pulmonary disease: e

20090054414 - Rufinamide for the treatment of post-traumatic stress disorder: Provided are methods of treating post-traumatic stress disorder with rufinamide. Also provided are methods of treating kindling and improving resilience with rufinamide. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of rufinamide and assessing at least one... Agent: Fenwick & West LLP

20090054418 - Antibacterial agents: 2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090054417 - Compounds and compositions as modulators of steroid hormone nuclear receptors: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear receptors.... Agent: Genomics Institute Of The Novartis Research Foundation

20090054419 - 3,7-diamino-10h-phenothiazine salts and their use: This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R1 and R9 is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB... Agent: Foley And Lardner LLP Suite 500

20090054420 - Bicyclic-substituted amines as histamine-3 receptor ligands: i

20090054422 - New oxabispidine compounds for the treatment of cardiac arrhythmias: There is provided compounds of formula I, wherein R1, R2, R3, R41 to R46, X, Y and Z have meanings given in the description, which compounds are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.... Agent: Pepper Hamilton LLP

20090054423 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090054424 - Optically active pyridine derivative and a medicament containing the same: e

20090054425 - Protein kinase inhibitors: and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by... Agent: Seed Intellectual Property Law Group PLLC

20090054421 - Pyrimidothiophene compounds having hsp90 inhibitory activity: Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R1 is -(Alk1)p-(Z)r(Alk2)-Q wherein AIk1 and AIk2 are optionally substituted divalent C1C3 alkylene or C2-C3 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO2—,... Agent: Banner & Witcoff, Ltd.

20090054426 - Treatment of central nervous system disorders: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising... Agent: Paul D. Yasger Abbott Laboratories

20090054427 - Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors: m

20090054428 - Novel pyrimidine derivatives 965: where R1, Q, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of... Agent: Astrazeneca R&d Boston

20090054429 - Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods: e

20090054430 - Inhibitors of protein kinases: Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090054432 - 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.... Agent: Wilson Sonsini Goodrich & Rosati

20090054431 - Novel heterocycle compounds: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090054433 - Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist: The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT3A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure,... Agent: The Nath Law Group

20090054434 - Isoquinolone derivatives as phosphodiesterase 10 inhibitors: e

20090054436 - Monocyclic heterocycles as kinase inhibitors:

20090054435 - Phenoxyalkanoic acid compound:

20090054437 - Nitrocatechol derivatives as comt inhibitors: New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090054438 - Compositions and methods for inhibiting growth and metastasis of melanoma: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or... Agent: Dla Piper LLP (us)

20090054439 - Sulfonamide derivatives, preparation and therapeutic application thereof: e

20090054442 - Method of administering ophthalmic fluids: A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration.... Agent: Hoffmann & Baron, LLP

20090054441 - Process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative: A substantially pure dextrorotatory isomer of zopiclone or a pharmaceutically acceptable salt thereof and crystalline forms thereof are provided. Also provided is a process for its preparation and pharmaceutical compositions containing same.... Agent: M. Carmen & Associates, PLLC

20090054440 - Quinoline derivatives as neurokinin receptor antagonists: The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of... Agent: Merck And Co., Inc

20090054443 - Compositions containing riboflavin and sesamin-class compounds: e

20090054445 - Amide substituted quinolines:

20090054446 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists:

20090054444 - Substituted phenylacetamides and their use as glucokinase activators: Compounds of Formula (I) wherein R1 is a cycloalkylsulphonyl group, or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.... Agent: Eli Lilly & Company

20090054447 - 2,3 substituted pyrazine sulfonamides as inhibitors of crth2: The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation,... Agent: Emd Serono Research Institute

20090054448 - Amino acid derivatives as histone deacetylase (hdac) inhibitors: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or stereoisomers thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative... Agent: Merck And Co., Inc

20090054449 - Substituted n-heterocyclic compounds and their use as dopamine d3 receptor ligands: and to the tautomers of the compounds the physiologically acceptable salts of the compounds and the physiologically acceptable salts of the tautomers of the compounds. The invention also relates to the use of these compounds and their pharmacologically acceptable salts in the production of a pharmaceutical agent for treating diseases... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090054450 - Compositions and methods of use for treating or preventing lipid related disorders: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions... Agent: Heslin Rothenberg Farley & Mesiti PC

20090054451 - Use of piperidine derivatives as agonists of chemokine receptor activity: s

20090054452 - Thienopyridine derivatives and the use thereof as hsp90 modulators: Novel thienopyridine derivatives of the formula (I), in which R1, R2, R3 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a... Agent: Millen, White, Zelano & Branigan, P.C.

20090054453 - Novel tetralins as 5-ht6 modulators: The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, R1, R2, R3, R4 and n are defined as in claim 1, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090054454 - Benzofuranyl- and benzothienyl- piperazinyl quinolines and methods of their use: Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and... Agent: Woodcock Washburn LLP/wyeth

20090054455 - Aripiprazole co-crystals: Co-crystals comprising aripiprazole and fumaric acid.... Agent: Dr. Reddy''s Laboratories, Inc.

20090054456 - Benzylpiperazine derivatives and their medical use: The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090054457 - Substituted heterocyclic compounds: e

20090054458 - Use of a polymorph of flibanserin for treating disease: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090054459 - Substituted indoles: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and... Agent: Millen, White, Zelano & Branigan, P.C.

20090054460 - Piperazine derivatives and methods of use: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject... Agent: Amgen Inc.

20090054461 - Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder: Use of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I), in racemic (R, S) form or in the form of the (S) enantiomer, in which R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090054463 - Derivatives of urea and related diamines, methods for their manufacture, and uses therefor: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.... Agent: Amgen Inc.

20090054464 - Hdac inhibitor: e

20090054462 - Hydroisoindoline tachykinin receptor antagonists: The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20090054465 - N-hydroxyacrylamide compounds: This invention relates to novel N-hydroxyacrylamide compounds of formula (I) and pharmaceutically acceptable salts thereof. More particularly, it relates to novel N-hydroxyacrylamide compounds and pharmaceutically acceptable salts thereof which act as a HDAC inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090054466 - Leukotriene b4 inhibitors: i

20090054467 - Pyrrolo pyrimidines as agents for the inhibition of cystein proteases: The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation,... Agent: Novartis Institutes For Biomedical Research, Inc.

20090054468 - New use 938: The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090054469 - Quinazolinone derivatives and their use as b-raf inhibitors: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20090054470 - Use of mitochondrial electron transport inhibitors to control fouling organisms: The present invention relates to the use of mitochondrial electron transport inhibitors (METI's) to control or combat fouling organisms. More particularly, the present invention relates to the use of mitochondrial electron transport inhibitors for protecting materials against fouling by marine or freshwater fouling organisms and an antifouling composition suitable for... Agent: Philip S. Johnson Johnson & Johnson

20090054472 - Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof: A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or... Agent: Sughrue Mion, PLLC

20090054471 - Pyridopyrazolopyrimidine compounds and their uses as anti-cancer and anti-diabete drugs: The present invention relates to pyridopyrazolopyrimidine derivatives that are useful pharmacological agents through the inhibition or antagonism of protein kinases, and to processes for the preparation and use of the same. In particular, the present invention relates to compounds that demonstrate protein tyrosine kinase and/or protein serine/threonine kinase inhibition.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090054473 - Therapy for complications of diabetes: A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in... Agent: Harness, Dickey, & Pierce, P.l.c

20090054475 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.... Agent: Townsend And Townsend And Crew, LLP

20090054474 - Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same: (wherein R1, R2, R3, R4 and R5 are the same or different, and represent hydrogen atom, a halogen atom, a lower alkyl group etc., R6, R7 and R8 are the same or different, and represent hydrogen atom, a halogen atom, a lower alkyl group etc., R9 and R10 are the... Agent: Greenblum & Bernstein, P.L.C

20090054476 - A3 adenosine receptor allosteric modulators: The present invention relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering... Agent: The Nath Law Group

20090054477 - 4-thio substituted quinoline and naphthyridine compounds: The present invention relates to 4-thio substituted quinoline and naphthyridine derivatives and processes for their preparation. The invention also related to methods for treating infection of Hepatitis C virus by administering a 4-thio substituted quinoline or naphthyridine derivative.... Agent: Fenwick & West LLP

20090054478 - Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases: The present invention relates to azolopyridin-3-one derivatives of the general formula I with the meanings indicated in the description, their pharmaceutically usable salts and their use as medicinal substances.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090054479 - Fused heterocyclic derivatives as ppar modulators: e

20090054480 - Novel quinuclidine carbamate derivatives and medicinal compositions containing the same: Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090054481 - Saquinavir mesylate oral dosage form: A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090054482 - Method of making and administering quinoline derivatives as anti-cancer agents: The present invention relates methods of preparing quinoline derivative compounds, and administering such compounds in the treatment of solid and non-solid tumors, notably on liver cancer.... Agent: Albert Cun-chi Chan

20090054484 - Substituted heteroaryl benzofuran acids: The present invention relates generally to substituted heteroaryl benzofuran acids and methods of using them.... Agent: Wyeth Patent Law Group

20090054483 - Substituted quinolines as inhibitors of leukotriene biosynthesis: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.... Agent: Merck And Co., Inc

20090054485 - Method of treating neutrophil-related diseases with topical anesthetics: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20090054486 - Polymorphic form xvi of fexofenadine hydrochloride: Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI.... Agent: Kenyon & Kenyon LLP

20090054487 - Pharmaceutical composition for increasing the mitochondrial genesis: The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition increasing the mitochondrial genesis.... Agent: Birch Stewart Kolasch & Birch

20090054488 - Isomigrastatin analogs in the treatment of cancer: The present invention provides compounds having formula (I): (I) wherein n, R1-R5, Ra-Rb, Q, Y1 and Y2 are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased... Agent: Choate, Hall & Stewart LLP Sloan-kettering Institute For Cancer Research

20090054489 - Multimediator dopamine transport inhibitors, and uses related thereto: The invention provides a class of DAT-5HT2 antagonists, packaged pharmaceuticals comprising such antagonists, and their uses in treating, or manufacturing medicaments for treating disease conditions, including a movement disorder, attention deficit disorder or attention-deficit hyperactivity disorder, anxiety, depression or psychotic disorder. Related business methods such as marketing the inhibitors to... Agent: Ropes & Gray LLP

20090054490 - Methods for the treatment of gerd with mglur5 antagonists: e

20090054491 - use: The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090054492 - Heterocyclyethylcarboxamide derivatives: e

20090054494 - N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use: And the isomers thereof wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090054493 - Thiazole derivatives as ppar delta ligands and their manufacturing process: The present invention relates to novel thiazole derivative compounds having activity for peroxisome prolif erator-activated receptor δ (PPARδ), as well as their intermediates and synthesis methods thereof.... Agent: Lowe Hauptman Ham & Berner, LLP

20090054495 - Ccr9 inhibitors and methods of use thereof: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula... Agent: Millennium Pharmaceuticals, Inc.

20090054496 - Microbiocides: The invention relates to a fungicidally active compound of the general Formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by the groups R3, R4 and R5; R1 and R2 are... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090054498 - Anhydrous compositions useful for attaining enhanced sexual wellness: The invention relates to an anhydrous composition comprising a vasodilator, for example, a niacin derivative, and an acceptable carrier wherein the vasodilator such as a niacin derivative, is present in an amount effective to increase the blood flow when the composition is applied to human tissue. The compositions according to... Agent: Philip S. Johnson Johnson & Johnson

20090054499 - Intermediate release nicotinic acid compositions for treating hyperlipidemia which exhibit an in vivo stair-stepped absorption curve: Intermediate release nicotinic acid formulations exhibiting an in vivo stair-stepped or sigmoidally-shaped absorption curves when the plasma nicotinic acid or nicotinuric acid curves are deconvoluted using the Wagner-Nelson method, which are suitable for oral administration once-a-day preferably during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity... Agent: Paul D. Yasger Abbott Laboratories

20090054497 - Methods for attaining enhanced sexual wellness using anhydrous compositions: The invention relates to a method of attaining enhanced sexual wellness of an individual comprising administering to the genital areas of the individual, an anhydrous composition comprising a vasodilator, for example, a niacin derivative, and an acceptable carrier. The method according to the invention does not cause flushing.... Agent: Philip S. Johnson Johnson & Johnson

20090054500 - Composition and methods useful in preventing cardiac hypertrophy: The present invention is directed to compositions and methods that can be used for preventing the hypertrophy of cardiac cells. The compositions and methods involve the use of compounds that lead to an increase in the cellular activity of the transcription factor CHF1.... Agent: Law Office Of Michael A. Sanzo, LLC

20090054501 - Azole compounds used as tuberculostatic and leishmanicide agents: where: X is an atom of “C” or “N;” where X is “N” the radicals do triazole ring are represented by: R1=COR2, CSR3, CN(R4)R5 or CF2R6; R2=H, NHNH2, alkyl, aryl substituted or not, OH, NR7R8 or OR9; R3=alkyl or aryl substituted or not; R4=H, OH, alkyl or aryl substituted or... Agent: Klarquist Sparkman, LLP

20090054502 - Benzimidazole derivative and use as angiotensin ii antagonist: e

20090054503 - Composition: Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately,... Agent: Banner & Witcoff, Ltd.

20090054504 - Modified release formulations of (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine and methods of using the same: Modified release pharmaceutical compositions (controlled release, sustained release, and/or extended release) of the R-(+) enantiomer of pramipexole (RPPX) and methods of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.... Agent: Pepper Hamilton LLP

20090054505 - Therapeutic oxazolidinones and thiazolidinones: d

20090054506 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20090054507 - Control of malignant cells by kinase inhibition: Inhibitors of casein kinase 2 are described that have been found to arrest uncontrolled cell proliferation, thereby suggesting their use in cancer treatment strategies. Specific applications include treating breast cancer, colon cancer, melanoma, chronic myelogenous leukemia, bladder cancer, renal cancer, and brain cancer. Various methods and compositions utilizing the inhibitors... Agent: Rankin, Hill & Clark LLP

20090054508 - Igf-1r inhibitor: {wherein R1 represents —NR4R5 [wherein R4 represents a hydrogen atom or the like, R5 represents substituted or unsubstituted lower alkyl, —C(═O)R6 (wherein R6 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and R2 and R3 may be the same... Agent: Fitzpatrick Cella Harper & Scinto

20090054509 - Octahydropentalene-substituted pyrazoline derivatives, their prepartion and use as medicaments: The present invention relates to octahydropentalene-substituted pyrazoline compounds of formula I, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. (1)... Agent: Banner & Witcoff, Ltd.

20090054510 - Method for identifying compounds for the treatment of depression: An assay for identifying compounds with increased efficacy in the treatment of depression is disclosed. The assay comprises the steps of determining whether a test compound inhibits SERT and whether it inhibits with an allosteric site ion SERT.... Agent: Darby & Darby P.C.

20090054511 - Tryptophan derivative and application thereof: wherein X represents a halogen atom; R1 represents a hydrogen atom, substituted or unsubstituted C1-6 alkyl group, substituted or unsubstituted C2-6 alkenyl group, substituted or unsubstituted C2-6 alkynyl group, substituted or unsubstituted aromatic group, substituted or unsubstituted aralkyl group, substituted or unsubstituted acyl group, substituted or unsubstituted arylsulfonyl group, substituted... Agent: Birch Stewart Kolasch & Birch

20090054512 - Use of organic compounds: A method for improving glucose control by administering a DPP-IV inhibitor to a patient in need thereof, before or with the evening meal.... Agent: Novartis Corporate Intellectual Property

20090054513 - Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease: A combination of constituents for oral administration by women with polycystic ovarian syndrome includes α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacture is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other... Agent: Hogan & Hartson LLP

20090054514 - Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders: c

20090054515 - Skin-whitening cosmetic: Disclosed are: a novel skin-whitening agent; and a skin-whitening cosmetic or quasi-drug which is highly effective for prevention/amelioration of melanopathy and is prepared using the skin-whitening agent. The cosmetic contains a compound represented by the general formula (I) and/or a salt thereof as an active ingredient. In the general formula... Agent: Knobbe Martens Olson & Bear LLP

20090054516 - Composition for treating cancer cells and synthetic method for the same: s

20090054518 - Ampelopsin unsaturated sodium salt preparation and applications thereof: A ampelopsin salt, its derivatives preparation and application are new. The ampelopsin salt being formed by substituting a monovalent cation for hydrogen atom on the ampelopsin, and the said substitution is a unsaturated substitution, is prepared by the reaction of ampelopsin with salify agent, and which is used for preparing... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090054517 - Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment: A new method is provided for inhibiting tumor growth and for delaying the onset of cancer. Several estrogenic compounds from plants are capable of inhibiting cell proliferation both in cell cultures and in whole animals. These compounds likely exert their anti-proliferation effects by inhibiting the Hedgehog signaling pathway. Estrogen receptors... Agent: Lathrop & Gage Lc

20090054519 - Derivatives of monosaccharides as 5-lipoxygenase inhibitors: The present invention relates to the use of derivatives of monosaccharides as 5-lipoxygenase inhibitor.... Agent: Ranbaxy Inc.

20090054520 - Oxalic acid derivatives and use thereof as physiological cooling active ingredients: The present invention relates to specific oxalic acid derivatives and to corresponding mixtures and to uses thereof as physiological cooling active ingredients.... Agent: Connolly Bove Lodge & Hutz LLP

20090054521 - Zwitterionic compounds and use thereof: The present invention covers zwitterionic, non-surface-active compounds in the form of carboxymethylated, short-chain dialkylaminoalkylamides and use thereof as therapeutic agent.... Agent: Scully Scott Murphy & Presser, PC

20090054522 - Hair care product: With an object of discovering a substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and of providing a hair care product... Agent: Posz Law Group, PLC

20090054523 - Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases: A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090054524 - Methods for identifying and using ikk inhibitors: The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the... Agent: Medlen & Carroll, LLP Suite 350

20090054525 - Selective androgen receptor modulators: A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090054526 - Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders: Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and/or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-ery-thro-2-(N-myristoylamino)-1-phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone),... Agent: Darby & Darby P.C.

20090054527 - Administration of capsaicinoids: Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasodilator.... Agent: Davidson, Davidson & Kappel, LLC

20090054528 - Bridged polycyclic compound based compositions for coating oral surfaces in pets: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090054529 - Flow path conditioner system: Compositions (3) and methods of using such compositions (3) to condition, clean, or disinfect the flow path of a conduit (8) of a microfluidic devices (16), such as flow cytometers or liquid chromatographs.... Agent: Cr Miles, P.C. Craig R. Miles

20090054530 - Methods and compositions that enhance bioavailability of coenzyme-q10: Bioavailability of Coenzyme-Q 10 (“Co-Q10”), an oil-soluble substance, can be enhanced in a subject by modifying, e.g. nanonizing or charging, the form of Co-Q10. Co-Q10 bioavailability also can be enhanced by administering Co-Q10 to the subject as an oil (lipid)-based and water (hydro)-based mixed composition, along with other optional components,... Agent: Hoffmann & Baron, LLP

20090054531 - Eye drop preparation comprising xanthan gum and terpenoid: The present invention provides an ophthalmic solution containing xanthan gum and terpenoid, which shows a suppressed decrease in the terpenoid content, by the addition of xanthan gum to an ophthalmic solution containing terpenoid.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090054532 - Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or... Agent: Wilson Sonsini Goodrich & Rosati

20090054534 - Bright pigment, method for production of the pigment, and cosmetic, coating, ink or resin composition comprising the pigment: A bright pigment including a scaly inorganic base 10 and a silver-based alloy coating 20 that covers the inorganic base 10 and that includes silver and at least one noble metal selected from the group consisting of gold, palladium and platinum, wherein the content of the noble metal is in... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090054533 - Film coating compositions based on tribasic calcium phosphate: Disclosed herein are dry film coating compositions comprising of tribasic calcium phosphate as one of the essential ingredient along with other commonly used polymers, plasticizers, excipients like suspending agents, pigments, lubricants, glidents, opacifiers, flavours, sweetener etc. for use in coating of pharmaceutical tablets, nutritional supplements, food products, confectionery, agricultural seeds... Agent: Blank Rome LLP

20090054535 - Method for embolization using liquid embolic materials: A method for embolization using liquid embolic materials is described. The method comprises the use of two liquid components. The first liquid component is an aqueous solution or dispersion comprising at least one oxidized polysaccharide. The second liquid component is either an aqueous solution or dispersion comprising at least one... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090054536 - palatable support of improved formula: A palatable support is intended to at least partially wrap an active substance that is initially independent of the support. The support of the invention is remarkable in that it includes, as a percentage by weight based on the total weight of the support, 3% to 50% of glucose syrup,... Agent: Oliff & Berridge, PLC

20090054537 - Therapeutic protocols using hyaluronan: The present invention relates generally to the field of therapeutics and in particular, chemotherapy. Even more particularly, the present invention provides therapeutic strategies which reduce the toxicity or enhance the efficacy of chemotherapeutic agents. Compositions and methods of treatment and prophylaxis are also contemplated by the present invention.... Agent: Morrison & Foerster LLP

  
02/19/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090048149 - Antagonists of the bradykinin b1 receptor: The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can... Agent: Amgen Inc.

20090048148 - Compositions and methods for therapeutic use: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such... Agent: Townsend And Townsend And Crew, LLP

20090048145 - In situ hardening paste, its manufacturing and use: An in-situ-hardening paste, containing an organic or inorganic filling material, a biodegradable polymer and a water soluble polymeric plasticizer was developed as a delivery system for an active agent with scaffold properties in the field of tissue regeneration. The hardened paste is sufficient mechanical stable to can be used as... Agent: Wolf Greenfield & Sacks, P.C.

20090048150 - Materials and methods for the detection of nitrated fibrinogen: Compositions are disclosed for detecting a patient's risk for coronary artery disease. The compositions can determine the presence of nitrated fibrinogen which is linked with coronary artery disease. Kits for the detection of coronary artery disease are also provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090048147 - Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules: m

20090048151 - Peg-poly(ortho ester) graft copolymers and pharmaceutical compositions: This invention relates to graft copolymer delivery vehicles comprising a polyethyleneglycol-poly(ortho ester), and to controlled release pharmaceutical compositions comprising the delivery vehicle and an active agent. The graft copolymer delivery vehicles may be thermogels graft copolymers. The pharmaceutical compositions may be in the form of a topical, syringable, or injectable... Agent: Foley & Lardner LLP

20090048146 - Use of agents that upregulate crystallin expression in the retina and optic nerve head: The present invention relates to methods to treat and/or prevent optic nerve damage in a subject by administering a composition comprising a crystallin agonist.... Agent: Alcon

20090048152 - Systems and methods for glycemic control during pump disconnection: Techniques and devices are described for allowing a diabetes patient to safely disconnect an insulin infusion system device for a time period. In one aspect, the techniques and devices can be implemented by receiving a maximum glucose amount, a minimum glucose amount, and a contemplated disconnection time; receiving a current... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090048153 - Composition for treating sulfur mustard toxicity and methods of using same: One embodiment of the present invention provides a composition, comprising, in amounts effective to treat sulfur mustard or half sulfur mustard induced toxicity or skin damage: an agent that inhibits alkylation of —SH and >NH protein groups; an agent that reduces —SS— to SH; a scavenger of reactive oxygen species;... Agent: Dla Piper LLP (us) Attn: Patent Group

20090048154 - Compositions and methods for treating diabetes: The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and/or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090048155 - Methods for preventing and treating tissue injury and sepsis associated with yersinia pestis infection: Methods for treating and preventing tissue injury and sepsis associated with a Yersinia pestis infection, particularly pneumonic plague, are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic... Agent: Alston & Bird LLP

20090048156 - Hdac inhibitors and hormone targeted drugs for the treatment of cancer: The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase... Agent: Fulbright & Jaworski, LLP

20090048165 - Anti-hiv agent: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP... Agent: Marshall, Gerstein & Borun LLP

20090048160 - Antimicrobial activity of bovine bactericidal/permeability-increasing protein (bpi)-derived peptides against gram-negative bacterial mastitis isolates: The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI65-99), 142-169 (bBPI142-169), or the combination of amino acids 90-99 and 148-161 (bBPI90-99,148-161) of bBPI. The bBPI90-99,148-161 peptide demonstrated the widest spectrum of... Agent: Usda, Ars, Ott

20090048161 - Cytokine receptor modulators and uses thereof: The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for... Agent: Clark & Elbing LLP

20090048167 - Disease treatment via antimicrobial peptides or their inhibitors: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The... Agent: Lucas & Mercanti, LLP

20090048169 - Identification of crmp4 as a convergent regulator of axon outgrowth inhibition: The present invention relates to the identification of the cytosolic phosphoprotein CRMP4b as a protein that physically and functionally interacts with RhoA to mediate neurite outgrowth inhibition. siRNA-mediated knockdown of CRMP4 promotes neurite outgrowth on myelin substrates indicating a critical role for CRMP4 in neurite outgrowth inhibition. Disruption of CRMP4b-RhoA... Agent: Ogilvy Renault LLP

20090048168 - Inhibitors of bcl-2: A purified polypeptide includes about 5 to about 80 amino acids and includes an amino acid sequence corresponding to a portion of SEQ ID NO:1. The polypeptide inhibiting binding of Bcl-2 to IP3 receptors of cells that express IP3R and Bcl-2.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090048158 - Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells: The use of fragments of IGFBP-4 for inhibiting angiogenesis and tumor growth is described.... Agent: Ade & Company Inc.

20090048159 - Kit for treating a health condition by inducing translocation of a calreticulin protein to a cellular membrane: A kit for treating a health condition in a mammal comprises a calreticulin protein and/or compound for inducing a translocation of a calreticulin protein to a cellular membrane in order to provoke an immunogenic apoptosis. The calreticulin protein may include any one or more of: endogenous calreticulin, recombinant calreticulin, and... Agent: Samuel A. Kassatly

20090048162 - Methods of treating neuronal disorders using mntf peptides and analogs thereof: The present disclosure relates to methods for treating neuronal disorders using a motoneuronotrophic factor (MNTF) or its peptide analogs. The present disclosure further relates to methods for treating a spinal cord injury, a neurodegenerative disease, a stroke or cerebral ischemia, Huntington's Disease, Parkinson's Disease, Multiple Sclerosis, amyotrophic lateral sclerosis (ALS),... Agent: Bio Technology Law Group C/o Portfolioip

20090048166 - Novel peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also... Agent: Darby & Darby P.C.

20090048163 - Nucleic acid and protein sequences of asporins: Mouse asporin protein and nucleic acid sequences are disclosed. The protein contains a unique aspartic acid region near the N-terminus. The central domain contains ten leucine rich repeats. Sequences consistent with other class I small leucine rich repeat proteoglycans (SLRP) are also observed. Methods of use for the protein include... Agent: Benjamin Aaron Adler, Ph.d., J.d. Adler & Associates

20090048170 - Target for anti-angiogenesis therapy: The present disclosure concerns the use of peptides and compositions, such as pharmaceutical compositions, to influence angiogenesis. Particular methods are useful for promoting angiogenesis, while others are particularly useful for inhibiting angiogenesis.... Agent: Klarquist Sparkman, LLP

20090048164 - Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same: The present invention relates generally to therapeutic molecules which are useful for modulating apoptosis in a target cell or cell population. More particularly, the present invention provides therapeutic agents which inhibit pro-survival molecules and which are capable of inducing or facilitating apoptosis of a target cell or cell population such... Agent: Knobbe Martens Olson & Bear LLP

20090048157 - Use of organic compounds: This invention relates generally to calcitonin and their use in bone growth. Specifically, the invention relates to the use of calcitonin, e.g. salmon calictonin, to stimulate new bone formation in patients in need thereof.... Agent: Novartis Corporate Intellectual Property

20090048175 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090048176 - Antibacterial agent: The invention concerns the use of substances that bind to the bacterial translation factor EF-Tu to inhibit the formation of a cytoskeleton in bacterial cells and for the production of antibacterial agents. In addition the invention concerns antibacterial agents which contain partial sections of the amino acid sequences of domains... Agent: Millen, White, Zelano & Branigan, P.C.

20090048174 - Methods for inhibiting angiogenesis and tumor growth by inhibition of beta or delta protein kinase c: Treatment methods for inhibiting tumor growth and angiogenesis are described. The methods involve treatment with an inhibitor of delta protein kinase C (δPKC) or an inhibitor of beta-II protein kinase C (βIIPKC), in an amount effective to decrease the rate of growth of a solid tumor and/or to inhibit tumor... Agent: Perkins Coie LLP

20090048177 - Methods for the treatment of mood disorders: The invention features methods of treating mood disorders, such as manic disorders, and stabilizing moods by administering a kappa agonist or partial agonist to a subject in need thereof.... Agent: Clark & Elbing LLP

20090048172 - Neuroprotective dietary supplement: The invention relates to a novel dietary supplement mixture having improved neuroprotective activity and preventing, ameliorating or counteracting neurodegeneration and preventing, counteracting and/or improving cognitive function decline. It also provides a dietary supplement, which is to be administered in an oral dosage form.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090048171 - Treatment of viral infections: The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections.... Agent: Davis Wright Tremaine LLP/los Angeles

20090048173 - Use of dipyridamole for treatment of resistance to platelet inhibitors: The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090048178 - Lps or lipid a binding agent and novel peptide: A lipopolysaccharide (LPS) and/or lipid A binding agent is provided. The LPS and/or lipid A binding agent contains an LPS and/or lipid A binding peptide, such as a peptide comprising an amino acid sequence of XYSSS (X=K, R, or H), or a derivative thereof, as an active ingredient. The LPS... Agent: Sughrue Mion, PLLC

20090048180 - Sustained-release preparation: l

20090048179 - Use of 5-phosphodiesterase inhibitors to enhance the permeability of the blood-brain barrier of abnormal brain tissue and the blood-tumor barrier: This invention relates to methods and kits for enhancing the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier. Particularly, methods comprising the administration of 5-phosphodiesterase inhibitors, such as sildenafil and vardenafil, to selectively enhance the permeability of the blood-brain barrier of abnormal brain tissue or... Agent: Davis Wright Tremaine LLP/los Angeles

20090048181 - Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a... Agent: Cooper & Dunham, LLP

20090048182 - Cosmetic use of at least one natural ac-n-ser-asp-lys-pro-tetrapeptide or one of its analogues as agent for slowing down loss of hair and/or stimulating hair growth: The invention concerns the cosmetic use of at least one compound of formula (I) wherein: A1 is the radical corresponding to D- or L-Ser; A2 is the radical corresponding to D- or L-Asp or Glu; A3 is the radical corresponding to D- or L-Lys, Arg or Orn; A4 is the... Agent: Foley And Lardner LLP Suite 500

20090048183 - Iap binding compounds: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using... Agent: Banner & Witcoff, Ltd.

20090048184 - Method for producing a drug extract that contains hydroxystilbene: The invention relates to a method for producing drug extracts that contain hydroxystilbene from a vegetable drug and to the use of various agents for pharmaceutical and non-pharmaceutical purposes.... Agent: Edwards Angell Palmer & Dodge LLP

20090048185 - Therapeutic drug for suppressing functions of nkt cells containing glycolipid derivative as active ingredient: e

20090048186 - Monosaccharide derivatives as anti-inflammatory and/or anti-cancer agents: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis,... Agent: Ranbaxy Inc.

20090048187 - Chemopreventive, anticancer and anti-inflammatory effects of pinoresinol-rich olives: The present invention relates to a composition and method for preventing and treating cancer and modulating cell proliferation using compositions extracted from pinoresinol-rich Olea europaea Caiazzana olives. The present invention provides contacting one or more cells with a pharmaceutical effective amount of a polyphenolic composition isolated from Olea europaea Caiazzana... Agent: Chalker Flores, LLP

20090048188 - Ophthalmic medicine composition: The present invention has an object to provide an ophthalmic pharmaceutical composition, particularly, an ophthalmic solution, ophthalmic ointment, ophthalmic wash, intraocular infusion solution, wash for anterior chamber, internal medicine, injection, or preservative for extracted cornea, which has improved therapeutic and/or prophylactic effects on the swelling, edema and walleye/cloudiness in the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090048190 - Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane: e

20090048189 - Tricyclic-nucleoside compounds for treating viral infections: Disclosed are tricyclic nucleoside compounds of formula (I), and methods thereof for treating viral infections mediated at least in part by a Flaviviridae family virus.... Agent: Foley & Lardner LLP

20090048193 - Administration of the reg1 anticoagulation system: An improved method of administration of an aptamer and antidote system to regulate blood coagulation in a host is provided based on weight adjusted or body mass index-adjusted dosing of the components of the system to provide a desired pharmacodynamic response. In addition, a method of reversing activity of the... Agent: King & Spalding LLP

20090048198 - Compositions and methods for nucleic acid delivery systems: The present invention relates to compositions and methods for use in delivering nucleic acids and other agents into cells and tissues. In particular, the present invention provides lipid mixtures at the gel-liquid crystalline phase transition providing superior lipofection activity for transferring materials into cells and tissues.... Agent: Casimir Jones, S.c.

20090048195 - Compositions and methods of sphingosine kinase inhibitors for use thereof in cancer therapy: The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention specifically relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and induce apoptosis in a variety of cancers.... Agent: Hogan & Hartson L.L.P.

20090048192 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified... Agent: Woodcock Washburn LLP

20090048200 - Gpr 26 g-protein coupled receptor: We disclose GPR26 G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding GPR26 polypeptide are also disclosed. The GPR26 receptor is useful in the diagnosis and therapy... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090048199 - Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use: The present invention concerns methods and compositions for identifying genes and/or proteins involved in hibernation, activators and/or inhibitors of such genes or proteins, and methods of therapeutic use of such activators and/or inhibitors for treatment of a wide variety of diseases and/or medical conditions. In particular embodiments, such hibernation-related genes... Agent: Fulbright & Jaworski L.L.P.

20090048197 - Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules: The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in... Agent: Sirna Therapeutics, Inc.

20090048196 - Membrane receptor for retinol binding protein mediates cellular uptake of vitamin a, methods of use and compositions: Provided is a method of diagnosing a condition associated with abnormal uptake of a retinoid comprising determining the amount of STRA6 expressed by a suspect cell and comparing the amount of expressed STRA6 in the suspect cell with the amount of expressed STRA6 in a normal cell. Also provided is... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090048191 - Therapeutic molecules for modulating stability of vegf: This present invention discloses nucleic acid compositions and methods that are useful for treating ischemic conditions in animals, particularly in mammals such as humans. Specifically, the invention discloses nucleic acid molecules comprising or encoding a sequence that modulates the stability of a transcript from a vascular endothelial growth factor gene,... Agent: Seed Intellectual Property Law Group PLLC

20090048201 - Use of targeted cross-linked nanoparticles for in vivo gene delivery: The in vivo delivery of nucleic acids is targeted by delivery of the nucleic acid in a complex with cross-linked nanoparticles; where the nanoparticles comprise cross-linked neutral amphipathic molecules, cationic amphipathic molecules and targeting amphipathic molecules. Optionally the cationic and targeting amphipathic molecules are also cross-linked. A targeting moiety present... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090048194 - Vagal afferent neurons as targets for treatment: A method of identifying a compound capable of reducing or preventing prolonged sensory neuron hyper-excitability comprising the steps of: (a) administering the compound to an experimental non-human animal having prolonged sensory neuron hyper-excitability; (b) generating an expression profile of the genes modulated in the Nodose Ganglia (NG) of the animal... Agent: Woodcock Washburn LLP

20090048202 - Selective inhibitors of translesion dna replication: An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in FIG. 1.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090048203 - Substituted adenines and the uses thereof: This invention relates to compounds of Formula (I): and their use in the treatment of bacterial infections.... Agent: Astrazeneca R&d Boston

20090048205 - Combination therapy with synthetic triterpenoids and gemcitabine: The present invention concerns methods for treating cancer, such as pancreatic cancer, using combination therapies, including the combination of a synthetic triterpenoid, e.g., CDDO-Me, and gemcitabine.... Agent: Fulbright & Jaworski L.L.P.

20090048204 - Novel forms of cddo methyl ester: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior... Agent: Foley And Lardner LLP Suite 500

20090048206 - Edible powder meterial having excellent shelf stability: The present invention provides a powder material obtained by drying an aqueous emulsion containing at least one component selected from the group consisting of perfumes, coloring agents and functional substances, trehalose and water-soluble hemicellulose. This powder material has excellent shelf stability of the perfume, coloring agent and/or functional substance, and... Agent: John W. Crosby

20090048207 - Hydrazide-containing cftr inhibitor compounds and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise... Agent: Seed Intellectual Property Law Group PLLC

20090048209 - Compositions comprising dc-sign blockers and methods of using dc-sign blockers for preventing or treating diseases of a mammal, including viral infections: The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090048208 - Method for producing the low molecular weight beta-glucan by irradiation and low molecular weight beta-glucan produced by the method: Disclosed herein is a method for the preparation of low-molecular weight beta-glucan by irradiation. The low-molecular weight beta-glucan prepared by irradiation shows a random distribution of all beta-glucan structures, low viscosity and high water solubility, and acts as an excellent antioxidant and to activate immune cells, finding useful application in... Agent: Merchant & Gould PC

20090048210 - Agent for therapy or treatment of wound: The present invention has an object of revealing an epidermis regeneration effect of various chitin derivatives and providing an agent for therapy or treatment for wound which can be clinically used effectively. According to the present invention, it has been evidenced that N-acetyl-D-glucosamine has an effect of promoting proliferation of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090048211 - External preparation composition: e

20090048212 - Cosmetic composition comprising an oil: Cosmetic composition comprising an oil The present invention relates to a composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase, at least 5% by weight, relative to the total weight of the composition, of a dispersed solid phase and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090048213 - Prodrug of cinnamide compound: s

20090048214 - Methods for treating renal tumors using 2, 4-pyrimidinediamine drug and prodrug compounds: The present disclosure provides methods for the inhibiting proliferation of tumor cells, and methods for treating solid tumor cancers in a subject by administration of 2,4-pyrimidinediamine compounds.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090048215 - Compositions for ameliorating a reduced higher brain function resulting from organic brain lesions: A composition that has an activity of ameliorating reduced higher brain functions resulting from organic brain lesions, said composition comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid as well as docosahexaenoic acid and/or a compound having docosahexaenoic acid as a constituent fatty acid.... Agent: Drinker Biddle & Reath (dc)

20090048216 - Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor: c

20090048218 - 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative: The 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, in which R is hydrogen or C1-C4-alkyl, R4 is hydrogen or halogen, furthermore either: R6a, R6b together... Agent: Millen, White, Zelano & Branigan, P.C.

20090048217 - 17beta-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative: The 17β-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, in which R is hydrogen or C1-C4-alkyl, R4 is hydrogen or halogen, furthermore either: R6a, R6b together... Agent: Millen, White, Zelano & Branigan, P.C.

20090048220 - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090048219 - Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use: The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions... Agent: Wilmerhale/dc

20090048221 - Conjugates with anti-inflammatory activity: and Z represents a steroid or nonsteroidal subunit derived from steroid or nonsteroidal (NSAID) drugs with anti-inflammatory activity are disclosed. Pharmaceutically acceptable salts and solvates of such compounds, processes and intermediates for their preparation, as well as to the improved therapeutic action and the use in the treatment of inflammatory... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090048222 - Triaza compound immunoregulatory agents: The invention provides certain macrocyclic triaza compounds which down-regulate CD4 expression for use in the treatment of autoimmune diseases and inflammatory diseases or conditions. In a specific embodiment, the invention provides certain naphthalene substituted triaza macrocycles which exhibit high activity for down regulation of CD4 expression. In particular, triaza macrocycles... Agent: Greenlee Winner And Sullivan P C

20090048224 - Compounds and methods of use: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090048223 - Sulfonamide compound: A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G2 represents a halogen atom, hydroxyl group,... Agent: Birch Stewart Kolasch & Birch

20090048226 - Inhibitors of caspases: The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1β converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be... Agent: Ropes & Gray LLP

20090048227 - Substituted-1-phthalazinamines as vr- 1 antagonists: Substituted piperidine compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium... Agent: Merck And Co., Inc

20090048225 - Histamine h3 receptor agents, preparation and therapeutic uses: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of... Agent: Eli Lilly & Company

20090048228 - Heterocycle derivatives as histone deacetylase (hdac) inhibitors: e

20090048229 - Methods for promoting wakefulness: The present invention relates to methods of promoting wakefulness in an individual by administering a carbamoyl ester or a pharmaceutically acceptable salt thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090048230 - Compounds and compositions useful as cathepsin s inhibitors: e

20090048231 - Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions: The present invention provides new substituted prolinamides of the general formula (I) in which D, L, E, G, J, M, R3, R4, R5, and R13 are defined as in claim 1, their tautomers, their enantiomers, their diastereomers, their mixtures and their salts, more particularly their physiologically tolerated salts with organic... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090048232 - Compositions and methods for prophylaxis and treatment of addictions: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic... Agent: Seed Intellectual Property Law Group PLLC

20090048233 - Enhancing the tolerability of a seratonin antagonist and a nsri, a snri or a rima by using them in combination: Provided are combinations of pharmaceutical agents capable of eliciting a therapeutic effect. A first therapeutic agent in the combination has 5HT2/5HT3 antagonist and alpha-2 antagonist activity. A second therapeutic agent possesses both serotonin reuptake inhibitory activity and norepinephrine reuptake inhibitory activity or is a reversible inhibitor of monoamine oxidase A... Agent: Wilson Sonsini Goodrich & Rosati

20090048234 - Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke,... Agent: Franklin Volvovitz

20090048236 - New phenylalanine derivatives: Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the α4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090048235 - Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators: e

20090048237 - Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms: Dosage forms for procedural sedation and analgesia comprising the combination of an opioid such as sufentanil and a benzodiazepine such as triazolam for administration via the oral transmucosal route and methods for using the same are provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090048238 - Novel biaryl derivatives: s

20090048239 - Therapeutic compounds: A class of macrocyclic compounds of formula (I), wherein R7, A, Ar, B, D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the... Agent: Merck And Co., Inc

20090048240 - Antibacterial agents: This invention provides compositions which are 1,3-oxazinan-2-one compounds of formulae (I) and (II), and oxazolidinone compounds of formula (III): wherein R is a hydrocarbyl group, a heterocyclic group, a hydrocarbyl group having at least one substituent, or a heterocyclic group having at least one hydrocarbyl substituent, wherein the substituent on... Agent: Mcglinchey Stafford, PLLC Attn:IPGroup

20090048241 - Condensed imidazole derivatives as aromatase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R1, R2, R3, Q, m and n have the meanings explained in detail in the description, and * designates an asymmetric carbon atom, a process for their preparation... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090048242 - (1,10b-dihydro-2-(aminoalkyl-phenyl)-5h-pyrazolo[1,5 c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors: The present invention relates to 5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as inhibitors of the viral replication of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present HIV inhibitors with other anti-retroviral... Agent: Philip S. Johnson Johnson & Johnson

20090048243 - Therapeutic agent for attention-deficit hyperactivity disorder: A prophylactic and/or therapeutic drug for AD/HD, containing teniloxazine or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as the active ingredient.... Agent: Leydig Voit & Mayer, Ltd

20090048246 - Compounds, compositions and methods for reducing lipid levels: Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and... Agent: Joseph P. Meara Foley & Lardner LLP

20090048245 - Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases: m

20090048244 - Pyrrolotriazine compounds as kinase inhibitors:

20090048247 - Condensed isoxaline derivatives as inhibitors of phosphodiesterase type - iv: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory... Agent: Ranbaxy Inc.

20090048248 - Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists: The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20090048249 - 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders: e

20090048251 - 4-(1h-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer:

20090048250 - Indazolinone compositions useful as kinase inhibitors: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited... Agent: Vertex Pharmaceuticals Inc.

20090048252 - Thiazolones for use as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090048253 - Benzenoid ansamycin derivative: v

20090048254 - Salts and polymorphs of a vegf-r inhibitor: The invention relates to salts and free base forms of N,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide. The invention further relates to pharmaceutical compositions of these salts and free base forms and methods of treating disorders such as cancer using such compositions.... Agent: Pfizer Inc

20090048255 - Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs: e

20090048256 - Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity:

20090048257 - Compounds that modulate ppar activity, their preparation and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same.... Agent: High Point Pharmaceuticals, Inc.

20090048258 - Amide compound: v

20090048259 - Phthalazine compounds, compositions and methods of use: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.... Agent: Amgen Inc.

20090048262 - Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer: The present invention relates to compositions comprising a combination of 10-propargyl-10-deazaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer, and methods of treatment for non-small cell lung cancer in a patient in need thereof comprising administering for combination of 10-propargyl-10-deazaminopterin and an EGFR Kinase... Agent: Swanson & Bratschun, L.L.C.

20090048261 - Pharmaceutical composition for treatment of ocular hypertension: The present invention is related to the pharmaceutical industry in general and in particular with the pharmaceutical industry of production of ophthalmic compositions. More specifically, the present invention relates to the pharmaceutical industry of production of ophthalmologic compositions for the treating of ocular hypertension. The advantage of the present invention... Agent: Intellectual Property Law Group LLP

20090048260 - Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells: The invention relates to the use of pyrrolopyrazine derivatives for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2 and R3 independently=H, C1-C6 straight or branched chain optionally-substituted alkyl, R6=an aromatic ring Ar or cycloalkyl, optionally substituted, said... Agent: Wilmerhale/boston

20090048263 - Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder: A compound represented by the formula (I) or a salt thereof; and an agent for protecting a brain/neuronal cell or a therapeutic agent for sleep disorder comprising the compound or salt: wherein Z represents an oxygen or sulfur; R1 represents an aryl or heterocyclic group which may be substituted, provided... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090048264 - Piperazine amide derivatives: c

20090048265 - Novel antitumor agents and methods of their use: Antitumor compounds based on the α1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells.... Agent: Calfee Halter & Griswold, LLP

20090048266 - Effects of inhibitors of fgfr3 on gene transcription: Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.... Agent: Novartis Corporate Intellectual Property

20090048267 - Medicaments for the treatment or prevention of fibrotic diseases: t

20090048268 - Anti-histamine compositions and use thereof: The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20090048269 - Chemical compounds-821: or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβR1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and... Agent: Astrazeneca R&d Boston

20090048270 - Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls: Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other... Agent: Stout, Uxa, Buyan & Mullins LLP

20090048271 - Heterocyclic compounds and uses as anticancer agents: Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a heteroaryl five-membered ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which... Agent: Morrison & Foerster LLP

20090048272 - Preparation of paliperidone: Processes for preparing paliperidone.... Agent: Dr. Reddy''s Laboratories, Inc.

20090048273 - Premature ovulation preventive agent: The present invention provides a premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process, which contains a nonpeptidic compound having a gonadotropin releasing hormone antagonistic action. The premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process of the present invention is low... Agent: Edwards Angell Palmer & Dodge LLP

20090048274 - Pyrazolo[3,4-d]pyrimidine derivatives: Disclosed are novel pyrazolo[3,4-d]pyrimidine derivatives that are inhibitors of Raf kinase. These compounds and their pharmaceutically-acceptable salts and esters are anti-proliferative agents useful in the treatment or control of proliferative disorders such as solid tumors, in particular breast tumor, colon tumor, lung tumor, prostate tumor, and melanoma. Also disclosed are... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090048275 - Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith: Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-cyclohexan-1-ol, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.... Agent: Jones Day

20090048276 - Inhibitors of fatty acid synthase (fas): The instant invention provides for compounds which comprise substituted 3-aryl-4-hydroxyquinolin-2(1H)-ones that inhibit FAS activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting FAS activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20090048277 - Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof: in the form of a base or of an addition salt with an acid which is pharmaceutically acceptable, in the form of hydrates or of solvates, and also in the form of enantiomers, diastereoisomers and a mixture thereof. The disclosure also relates to processes for preparing said compounds, to pharmaceutical... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090048278 - Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels: This invention relates to novel quinazoline-2,4-diamine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20090048279 - Quinazoline analogs as receptor tyrosine kinase inhibitors: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor... Agent: Mcdermott Will & Emery LLP

20090048280 - Process for the preparation of substituted phenylalanines: Intermediates and synthetic processes for the preparation of substituted phenylalanine-based compounds (e.g., of Formula I) are disclosed:... Agent: Lexicon Pharmaceuticals, Inc.

20090048281 - Organic compounds: Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a... Agent: Novartis Corporate Intellectual Property

20090048282 - Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system: The present invention relates to pyrimidine sulfonamide analogs, methods of making pyrimidine sulfonamide analogs, compositions comprising a pyrimidine sulfonamide analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a pyrimidine sulfonamide analog.... Agent: Wyeth Patent Law Group

20090048283 - Salt of an androgen receptor modulator: The biphthalate salts of compound I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced... Agent: Merck And Co., Inc

20090048284 - Therapeutic compounds: This invention to antagonists that inhibit transporters and receptors. The invention also relates to partial inhibitors of transporters and receptors that allow partial transport or partial binding of a compound to the transporter or receptor. The invention also relates to compounds that differentially prevent transport or binding through a transporter... Agent: Edwards Angell Palmer & Dodge LLP

20090048285 - Pyrrolopyridines useful in the treatment of inflammation: There is provided compounds of formula (I), wherein X1, R1, R2, Y1, Y2, Y3 and Y4 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired... Agent: Morgan Lewis & Bockius LLP

20090048287 - Compositions useful for treating gastrointestinal motility disorders: The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HT3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090048286 - Inhibitors of protein tyrosine phosphatase 1b: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.... Agent: Wyeth Patent Law Group

20090048288 - Method of treating stress-mediated depression: The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment... Agent: Darby & Darby P.C.

20090048289 - Administration of tropisetron for treating inflammatory skin diseases/disorders: Tropisetron or salt thereof, formulated into diverse pharmaceutical/dermatological compositions, is useful for the treatment of a variety of inflammatory skin disorders/diseases, e.g., eczema, psoriasis, rosacea, acne vulgaris, ulcers, seborrhoeic dermatitis and irritations induced by chemical, physical or mechanical agents, notably rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090048290 - 2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-benzyofuran-2-carboxamide, novel salt forms, and methods of use thereof: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090048291 - Novel piperidine-4-acetic acid derivatives and their use: e

20090048292 - Synergistic combination:

20090048294 - Hif-1 alpha activating agent: The present invention relates to a HIF-1α activator containing clioquinol and its derivatives as an active ingredient. Clioquinol and its derivatives of the invention inhibit HIF-1α (hypoxia-inducible factor-1α) ubiquitination in normoxic cells and thus accumulate HIF-1α. In the meantime, CQ inhibits FIH-I activity and thereby induces transcription activity of the... Agent: Klarquist Sparkman, LLP

20090048296 - High concentration local anesthetic formulations: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20090048293 - Methods for treating bacillus infection: The present invention provides compositions and methods for detecting, treating, and preventing microbial infection, especially infection caused by Bacillus anthracis (“anthrax”).... Agent: Millen, White, Zelano & Branigan, P.C.

20090048295 - Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof: Substituted 5,6,7,8-tetrahydroquinoline derivatives, which are C5a receptor modulators, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, immune and inflammatory diseases and conditions, are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090048297 - 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication: The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions... Agent: Cantor Colburn, LLP

20090048298 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: e

20090048299 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, p, s, t, W, Ar1, X1, R1, R2, R3, R4, R6, and R7 areas defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods... Agent: Theravance, Inc.

20090048300 - Heterocyclic compounds: The present invention relates to compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to heterocyclic compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with... Agent: Connolly Bove Lodge & Hutz LLP

20090048301 - Heterocyclic compounds and their use as anticancer agents: The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090048302 - Methods and compositions for the treatment of conditions related to gastric acid secretion: e

20090048304 - Crystal form of besipirdine chlorhydrate, process preparation and use thereof: Crystal form of besipirdine chlorhydrate (Form I) corresponding to the Formula (A) below: the aforementioned form being characterized at least by one of the following physico-chemical properties: a) In FTIR, it displays at least the following absorption bands of the infrared spectrum: 778, 1198, 1121, but not the following absorption... Agent: Oliff & Berridge, PLC

20090048303 - Indole-2-carboxamidine derivatives as nmda receptor antago: The present invention relates therefore first to new indole-2-carboxamidine derivatives of formula (I)—wherein the meaning of X is hydrogen or halogen atom, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl group, Y, V and Z independently are hydrogen or halogen atom, hydroxy, cyano, C1-C4 alkylsulfonamido optionally substituted by a halogen atom or halogen... Agent: K.f. Ross P.C.

20090048305 - Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections: e

20090048306 - Pyridine derivatives:

20090048307 - 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of: wherein R1 represents hydrogen, hydrocarbon, heterocycle, amino, acyl, R2 represents an aromatic group, R3 represents hydrogen, pyridyl, aromatic hydrocarbon, X represents oxygen, optionally oxidized sulfur, Y represents a bond, an oxygen, optionally oxidized sulfur, a group represented by the formula NR4 (R4 represents hydrogen, hydrocarbon or acyl) and Z represents... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090048308 - Vla-4 antagonists: 4-Thio, 4-sulfinyl and 4-sulfonyl proline derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells... Agent: Merck And Co., Inc

20090048309 - N-(2-substituted phenyl)-n-methoxycarbamates and their preparation and use thereof: Compounds according to the present invention have very good fungicidal activities and can be used for the control of plant fungicidal diseases, such as wheat powdery mildew, melon powdery mildew, apple powdery mildew, grape powdery mildew, strawberry powdery mildew, wheat rust, soybean rust, wheat Pythium root rot, cucumber Alternaria blight,... Agent: Smith, Gambrell & Russell

20090048310 - Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus: m

20090048311 - Compostions and methods for controlling nematodes: Compositions and processes for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include oxazoles, oxadiazoles and thiadiazoles.... Agent: Fish & Richardson PC

20090048312 - Plant pathogen resistance: Azelaic acid or its derivatives or analogs induce a robust and a speedier defense response against pathogens in plants. Azelaic acid treatment alone does not induce many of the known defense-related genes but activates a plant's defense signaling upon pathogen exposure.... Agent: Barnes & Thornburg LLP

20090048313 - 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof: 2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.... Agent: Genentech, Inc.

20090048314 - Treatment of duchenne muscular dystrophy: Provided are polymorphic forms of a compound useful in the treatment of Duchenne muscular dystrophy.... Agent: Jones Day

20090048315 - Method of alleviating chronic pain via peripheral glutaminase regulation: A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one glutaminase inhibitor. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed,... Agent: Dunlap Codding, P.C.

20090048317 - Formulations of candesartan: The present invention encompasses pharmaceutical compositions comprising candesartan and processes for preparing the same. In particular, a pharmaceutical composition comprising candesartan or a prodrug thereof or an analog thereof or a derivative thereof and at least one non-ionic surfactant, wherein the pharmaceutical composition has about 0.01% to about 10% of... Agent: Kenyon & Kenyon LLP

20090048318 - Methods for treating degenerative diseases/injuries: Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090048316 - Pharmaceutical composition comprising candesartan cilexetil: The present invention encompasses pharmaceutical compositions comprising candesartan cilexetil, an amino acid and a pharmaceutically acceptable excipient, and processes for preparing the same.... Agent: Kenyon & Kenyon LLP

20090048319 - Method of using a micronutrient as safener for a triazole for controlling harmful fungi: A method of using a micronutrient selected from the group consisting of salts and adducts of Mg, Ca, B, Mn, Fe, Co and Zn and Mo as a safener for a triazole, selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, enilconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol,... Agent: Birch Stewart Kolasch & Birch

20090048320 - Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase: The present invention provides compounds and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.... Agent: Wyeth Patent Law Group

20090048321 - Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex: e

20090048322 - Parenteral and oral formulations of benzimidazoles: Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic... Agent: Benjamin Aaron Adler Adler & Associates

20090048323 - Substituted imidazoline compounds: o

20090048324 - Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules: A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090048325 - Prophylactic or therapeutic agent for irritable bowel syndrome: c

20090048326 - Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor:

20090048327 - Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors: The present invention relates to polymorphs of the 3-pyrrole substituted 2-indolinone compound 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide.... Agent: Pharmacia & Upjohn

20090048328 - Compound comprising prodigiosin from serratia macescence b-1231 kctc 0386bp for prevention and treatment of acute graft-versus-host disease: This invention relates to a composition for the prevention and treatment of acute graft-versus-host disease comprising prodigiosin isolated from Serratia marcescence B-1231 KCTC 0386BP, as an effective ingredient. The prodigiosin is immunosup-pressive by selectively suppressing the proliferation of T-cells through the suppression of the expression of IL-2 receptors, which is... Agent: Buchanan, Ingersoll & Rooney PC

20090048329 - Substituted pyrrolidine compounds with central nervous system activity: Provided herein are substituted pyrrolidines that demonstrate binding at biogenic amine transporters and can be synthesized by a methodology based on a chiral dirhodium catalyst. Compositions comprising substituted pyrrolidines can be used to treat central nervous system disorders such as schizophrenia.... Agent: Hodgson Russ LLP The Guaranty Building

20090048330 - Compound from antrodia camphorata and the use thereof: The present invention relates to novel compounds from Antrodia camphorata and the use thereof.... Agent: Harness, Dickey & Pierce, P.L.C

20090048331 - Methods and formulations for the delivery of pharmacologically active agents: In accordance with the present invention, novel formulations have been developed which are much more effective for the delivery of hydrophobic drugs to patients in need thereof than are prior art formulations. Invention formulations are capable of delivering more drug in shorter periods of time, with reduced side effects caused... Agent: Morrison & Foerster LLP

20090048332 - Natural novel antioxidants: New antioxidants derived from lichen extracts are reported; lecanoric acid, erythrin, sekikaic acid, and lobaric acid were reported as potent natural antioxidants for the treatment of disease and protection of products from the effect of oxidizing components.... Agent: Sarfaraz K. Niazi

20090048333 - Zearalenone macrolide derivatives and uses of the same: w

20090048334 - Sodium ascorbate solubilisate: The invention relates to a solubilisate consisting of an aqueous solution of the alkali salts and/or alkaline-earth salts of ascorbic acid for foodstuffs, cosmetics and or similar and consisting of an emulsifier with an HLB value of between 9 and 18, for example a polysorbate, which also comprises one or... Agent: Jacobson Holman PLLC

20090048335 - Process for preparing simvastatin: Preparation of simvastatin.... Agent: Dr. Reddy''s Laboratories, Inc.

20090048336 - Escitalopram oxalate powders: Escitalopram oxalate powders having definite particle size distribution parameters, processes for preparing the powders, and solid pharmaceutical formulations containing the powders.... Agent: Dr. Reddy''s Laboratories, Inc.

20090048337 - Modulation of anxiety through blockade of anandamide hydrolysis: I. are provided wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted... Agent: Townsend And Townsend And Crew, LLP

20090048338 - Biologically active oils: A process for the production of fats or oils and their extracts containing biologically active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes; b) incubating the inoculated substrate for a period of between about 7-120 days at a... Agent: Alston & Bird LLP

20090048339 - Compositions of cis-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof: The invention relates to use of the cis-9, trans-11 isomer of conjugated linoleic acid or a salt or ester thereof (cis-9, trans-11 CLA) and vaccenic acid or a salt or ester thereof (VA) to treat or prevent conditions associated with one or more of leukocyte infiltration, eosinophilia, airway remodelling, bronchoconstriction,... Agent: Knobbe Martens Olson & Bear LLP

20090048340 - Growth hormone secretion regulator: The present invention provides a growth hormone secretion regulator or an anti-aging agent comprising aspartic acid and valine as active ingredients. The present invention also provides a pharmaceutical, food, nutritional supplement (supplement), or feeding stuff comprising the growth hormone secretion regulator or anti-aging agent.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090048341 - Tranexamic acid formulations: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.... Agent: Davidson, Davidson & Kappel, LLC

20090048342 - Combination of bioavailable methionine with at least one essential oil: The invention concerns a food composition, designed to complement animal feed in methionine, said composition having a synergistic bactericidal effect on the bacterial activity of the bowel flora. Said food composition of bioavailable methionine comprises: a) a bioavailable methionine compound and b) at least one essential oil.... Agent: Oliff & Berridge, PLC

20090048343 - Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field: The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090048344 - Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid: Provided are compositions comprising aqueous suspensions of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid suitable for oral administration. Methods for making such compositions and methods for their stabilization are provided.... Agent: Novartis Corporate Intellectual Property

20090048345 - Immediate release and sustained release ibuprofen dosing regimen: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.... Agent: Philip S. Johnson Johnson & Johnson

20090048346 - Therapeutic formulations: The present invention features pharmaceutical compositions that improve the bioavailability of hydrophobic pharmaceutical agents that induce apoptosis in mammalian cells. Also featured are injectable formulations for the parenteral delivery of such hydrophobic pharmaceutical agents into patients in need of such treatment, as well as methods of making and using both... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090048347 - Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic: The invention relates to a drug delivery system for the topical administration of anesthetic agents. For example, a topical anesthetic for rapid local anesthesia is provided. The topical anesthetic includes an anesthetic, volatile and non-volatile solvents, and an optional thickener. In addition, a method is taught for applying the topical... Agent: Ropes & Gray LLP

20090048348 - Method for treating autism: A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090048349 - Compositions and kits for compounding pharmaceuticals: The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second... Agent: Wolf Greenfield & Sacks, P.C.

20090048350 - Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is... Agent: Sughrue Mion, PLLC

20090048351 - Benefit agent delivery compositions: Benefit agent delivery compositions, compositions, packaged products and displays comprising such benefit agent delivery compositions, and processes for making and using such benefit agent delivery compositions, compositions, packaged products and displays. Such compositions have improved deposition and retention properties that may impart improved benefit characteristics to a composition and/or situs.... Agent: The Procter & Gamble Company Global Legal Department - Ip

  
02/12/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090042770 - Branched chain amino acid chelate: Compositions are disclosed comprising mineral/branched-chain amino acid chelates such as, for example, calcium leucinate, for increasing absorption of the branched-amino acid in a human or animal subject. Methods are also provided for using the compositions to increase branched-chain amino acid absorption to increase or maintain muscle mass in athletes or... Agent: Donna J. Russell

20090042771 - Dietary lipids for improving skin and coat of pets: A source of dietary lipids containing anti-microbial fatty acids is added to a food composition intended for improving or maintaining the skin health and/or coat quality in a pet by preventing or regulating the growth of skin pathogens and of microflora responsible for the generation of body surface and coat... Agent: Bell, Boyd & Lloyd LLP

20090042769 - Modifications of peptide compositions to increase stability and delivery efficiency: The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.”... Agent: Morrison & Foerster LLP

20090042768 - Purine derivatives and their use for treatment of autoimmune diseases: e

20090042772 - Compounds and methods of treating insulin resistance and cardiomyopathy: Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular... Agent: Howson And Howson

20090042773 - P13 kinase gamma inhibitors for the treatment of anaemia: This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090042774 - Parathyroid hormone analogues and methods of use: The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090042792 - 18 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090042783 - Apo e analogs and methods for their use: Novel ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, cerebral ischema, Alzheimer's Disease and other brain disorders.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090042800 - Assay: A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired... Agent: Nixon & Vanderhye, PC

20090042795 - Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation: The present invention provide cardiac stem cell proliferation proteins and fragments thereof that promote proliferation and/or differentiation of cardiac stem cells. Also provided are methods of treating subjects with heart disease or defects, the methods comprising administering a cardiac stem cell proliferation protein or a fragment thereof to the subject... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090042799 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Dean G. Stathakis (t2-7h) Allergan, Inc.

20090042785 - Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4): The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and... Agent: Foley And Lardner LLP Suite 500

20090042775 - Defensin proteins: This invention relates to novel proteins, termed INSP 108 and INSP 109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090042796 - Derivatives of the il-2 receptor gamma chain, their production and use: This invention relates to the use of the IL-2 common gamma (cγc) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090042782 - Diagnostic and therapeutic strategies for conditions associated with the flj13639 gene: Provided are methods for determining a prognosis for an individual suspected of having or diagnosed with cancer, where a high CD24/low FLJ13639 ratio indicates an unfavorable prognosis. Also provided are methods for enhancing the activity of chemotherapeutic agents, and isolated, purified FLJ13639 proteins for use in improving the prognosis of... Agent: Hodgson Russ LLP The Guaranty Building

20090042776 - Fungal immunomodulatory protein (fip) prepared by microorganisms and uses thereof: The invention relates to an improved nucleic acid molecule encoding fungal immunomodulatory protein (FIP) that is better expressed in fungi, to vectors comprising the nucleic acid molecule, to hosts transformed with said vectors, to processes of expressing the protein of the invention in said transformed hosts, to the protein of... Agent: Harness, Dickey & Pierce, P.L.C

20090042777 - G-csf transferrin fusion proteins: A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that... Agent: Hogan & Hartson L.L.P.

20090042797 - Gamma-heregulin: A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. γ-HRG polypeptide and nucleic acid are... Agent: Morrison & Foerster LLP

20090042794 - Group b streptococcus antigens and corresponding dna fragments: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.... Agent: Seed Intellectual Property Law Group PLLC

20090042791 - Integrin binding motif containing peptides and methods of treating skeletal diseases: Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in... Agent: Bozicevic, Field & Francis LLP

20090042786 - Kunitz-type recombinant inhibitor: The present invention presents a Kunitz-type recombinant inhibitor obtained from a gene cloned from a cDNA library of salivary glands of the Amblyomma cajennense, and the inhibitor named Amblyomin-X has molecular mass of 13,500 Da.... Agent: Fish & Richardson PC

20090042789 - Method for improving symptom of mood disorder: The present invention relates to a method for improving symptom of mood disorder or its related disorder comprising a step of allowing activated-type Gm1 protein and the like to be excessively present in a brain of a mammal, and a non-human mammal, to which the method has been applied, and... Agent: Panitch Schwarze Belisario & Nadel LLP

20090042801 - Method for inhibiting infection and reproduction of influenza type a wsn virus: The present invention relates to a method for inhibiting infection and reproduction of influenza type A WSN virus, which comprises providing an effective amount of a pharmaceutical composition; and contacting said composition with said influenza type A WSN virus, wherein said pharmaceutical composition contains C-phycocyanin (C-PC), allophycocyanin (APC), and spirulina... Agent: Bacon & Thomas, PLLC

20090042778 - Methods for suppressing neovascularization using ephrinb2: Methods for inhibiting DNA synthesis, MAP kinase activation, and tube formation of endothelial cells are provided. Also provided are methods for inhibiting angiogenesis and neovascularization, as well as compositions useful for the methods described herein.... Agent: Osha Liang L.L.P.

20090042781 - Methods for treating diabetes: Methods for treating diabetes by increasing the insulin secretion by administration of a GLP-1 receptor agonist and/or a DPP-IV inhibitor in combination with a proton pump inhibitor and optionally a PPAR agonist are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090042780 - Modified tgf-beta superfamily polypeptides and related methods: The disclosure relates to modified TGF-beta polypeptides. Certain modified polypeptides disclosed herein are chimeric, containing a conserved framework portion from one protein of this family (e.g., Nodal) and variable loops that mediate receptor interaction derived from a second protein of this family (e.g., BMP-2). The chimeras will generally be designed... Agent: Ropes & Gray LLP

20090042793 - Novel antiviral therapies: The field of the invention relates to the use of carbohydrate binding compounds as a medicine, their use to treat or prevent viral infections, their use to manufacture a medicine to treat or prevent viral infections and their use in a vaccination strategy. The present invention relates to the use... Agent: Clark & Elbing LLP

20090042788 - Peptides and chemical compound for inhibition of shp2 function: The present invention relates to the inhibition of the function of SHP2 by both anti-SHP2 peptides and the chemical compound 4-(2-sulfaminoethyl)benzoic acid, SEBA, and SEBA derivatives binding to the phosphotyrosyl phosphatase domain of SHP2 thereby inhibiting the function of SHP2 both in vitro and in vivo. In addition, the inhibition... Agent: West Virginia University Research Corporation

20090042787 - Proteolytically cleavable fusion proteins with high molar specific activity: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090042784 - Purification of a drug substance of a factor vii polypeptide by removal of desgla-factor vii polypeptide structures: The present invention relates to a purification process for drug substances of a Factor VII polypeptide having an impurity in the form of desGla-Factor VII polypeptide structures. The process utilizes an anion-exchange material and includes washing and/or elution with a buffer of a predetermined pH.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090042779 - Purified extract of an alpha-amylase inhibitor from phytoemagglutinin-essentially free beans, process for its extraction and compositions containing it: The invention relates to the use of beans essentially free from phytohemagglutinin for extracting the alpha-amylase inhibitor (hereinafter also “phaseolamin”), the extract enriched in phaseolamin, the highly purified extract, and also the dietetic and pharmaceutical compositions that contain it; the invention also relates to a process for preparing the above... Agent: Nixon & Vanderhye, PC

20090042798 - T cell receptors and related materials and methods of use: The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated... Agent: Leydig, Voit & Mayer, Ltd.

20090042790 - Transmucosal delivery of peptide derivatives: What is described is a biological agent, comprised of a biologically active protein, or a fragment or a mimetic thereof, conjugated to at least one poly(alkylene oxide) chain having a size less than about 20 kDa, pharmaceutical formulations for intranasal delivery of said biological agent, or uses of said biological... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20090042802 - Compounds and peptides that bind the kgf receptor: The present invention relates to peptide compounds that bind the KGF receptor. The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with defective or insufficient epithelial cell proliferation. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090042803 - Inhibitors of protein kinases and uses thereof: Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to... Agent: Weaver Austin Villeneuve & Sampson LLP

20090042804 - Novel peptide amphiphiles having improved solubility and methods of using same: Disclosed herein are novel peptide amphiphile molecules and compositions discovered to possess improved solubility in aqueous buffers which, in turn, facilitates purification required for pharmaceutical applications, particularly for in vivo administration to human patients. In addition, gels of such peptide amphiphile compositions are shown herein to possess unexpectedly superior gelation... Agent: Smith Patent Consulting Consulting, LLC

20090042807 - Oligopeptide treatment of ischemia reperfusion injury: The invention relates to the modulation of gene expression in a cell, also called gene control, in particular, in relation to the treatment of ischemic-reperfusion injury. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a... Agent: Trask Britt

20090042805 - Peptides useful as dual caspase-2/-6 inhibitors and their biological applications: The invention relates to peptides having a core sequence selected in the group comprising: SEQ ID No.1: VDEAD, SEQ ID No.2: LDEGD, SEQ ID No.3: VDEGD, SEQ ID No.4: VDESD, SEQ ID No.5: LDEKD, SEQ ID No.6: FDESD, SEQ ID No.7: LDEAD, application as inhibitors of caspase-2 and/or -6 activity.... Agent: Nixon & Vanderhye, PC

20090042806 - Transglutaminase inhibitors and methods of use thereof: Transglutaminase inhibitors and methods of use thereof are provided.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090042808 - Use of mitochondria-targeted electron scavengers as anti-inflammatory agents: Provided herein are methods for using mitochondria-targeted electron scavengers as anti-inflammatory agents. The mitochondria-targeted electron scavenger comprises a free radical-scavenging group covalently linked to a mitochondria-targeting group derived from a hemigramicidin moiety. The mitochondria-targeted electron scavenger can be used to treat medical conditions associated with acute or chronic inflammation.... Agent: Jesse A. Hirshman, Esq.

20090042809 - Blood pressure lowering protein hydrolysates: The present invention describes the tripeptide MAP and/or the tripeptide ITP and/or a salt thereof.... Agent: Nixon & Vanderhye, PC

20090042810 - Ampk deficient animals, screening methods, and related therapeutics and diagnostics: The invention provides transgenic Drosophila embryos comprising in the germ cells an adenosine monophosphate-activated protein kinase (AMPK) null mutation. The transgenic Drosophila embryos are useful in screening drug candidates for treatment of a disease, such as cancer, kidney disease, diabetes, intestinal disease, and obesity. The invention further provides methods for... Agent: Medlen & Carroll, LLP

20090042812 - Lipase inhibitors: e

20090042811 - Synthesis of glycerolipid carbamates and dicarbamates and their use as an antitumor compounds: The syntheses and in vitro antitumor properties of carbamate-containing, dicarbamate-containing, and ureido-containing phospholipid compounds that have an ether linkage at the C-1 position of a glycerol backbone, a carbamate, dicarbamate, or ureido moiety at the C-2 position of the glycerol backbone, and a phosphocholine, phosphonocholine, or glycoside moiety at the... Agent: Ade & Company Inc.

20090042813 - Hoodia extract oil compositions comprising medium chain triglycerides: Oil compositions containing Hoodia plant extract dissolved in medium chain tri-acyl-glycerides. Edible emulsions comprising the inventive oil compositions are also disclosed.... Agent: Unilever Patent Group

20090042814 - Treatment and diagnosis of obligate intracellular pathogens: This invention relates to the detection of pathogens, in particular persistent forms of obligate intracellular or membrane associated microorganisms such as Chlamydia, Mycoplasma and Ureaplasma species, in blood samples, in particular in plasma and serum samples. Methods and kits of the invention may be useful in detecting pathogen infections and... Agent: Clark & Elbing LLP

20090042815 - Macrolide synthesis process and solid-state forms: This invention relates to a method for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides.... Agent: Intervet/schering-plough Animal Health Patent Department

20090042816 - Synthetic ligands for the differentiation of closely related toxins and pathogens: Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein.... Agent: Ulmer & Berne, LLP Attn: Diane Bell

20090042818 - Liquiritigenin and derivatives as selective estrogen receptor beta agonists: The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20090042817 - Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases: The invention relates to the use of a combination of active ingredients, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or... Agent: Edwards Angell Palmer & Dodge LLP

20090042819 - Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use: The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides... Agent: Wilmerhale/dc

20090042822 - Method to enhance delivery of glutathione and atp levels in cells: A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090042821 - Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.... Agent: Ranbaxy Inc.

20090042820 - Tubulin binding anti cancer agents and prodrugs thereof: Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20090042823 - Uses of broad spectrum rnai therapeutics against influenza: Methods and uses of RNAi-inducing agents for medicaments and treating or preventing a viral infection.... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20090042827 - Antiviral oligonucleotides targeting hbv: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for... Agent: Ogilvy Renault LLP

20090042825 - Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090042828 - Methods and compositions for treating gain-of-function disorders using rna interference: The present invention relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS), with RNAi agent. The invention further provides RNAi resistant replacement genes containing mismatches with their respective RNAi... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090042824 - Methods and kits for linking polymorphic sequences to expanded repeat mutations: Methods and kits are provided for determining which single nucleotide polymorphism (“SNP”) variant of an allele of a heterozygous patient is on the same allele as a disease-causing mutation that is at a remote region of the gene's mRNA comprising a) an allele specific reverse transcription reaction using an allele... Agent: Fox Rothschild LLP Medtronic, Inc.

20090042830 - Novel oncogene, recombinant protein derived therefrom, and uses thereof: The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a... Agent: Sughrue Mion, PLLC

20090042829 - Nucleic acid-lipopolymer compositions: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090042826 - Use of the axl receptor for diagnosis and treatment of renal disease: The invention is directed to a process of identifying a compound capable of inhibiting the activity of a human Axl receptor that comprises contacting the Axl receptor or cells expressing the Axl receptor with the compound; measuring the Axl receptor activity in the presence of the compound; and comparing the... Agent: Cooper & Dunham, LLP

20090042831 - Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection: 5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection.... Agent: Moore & Van Allen PLLC

20090042832 - Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same: New salts or ion pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or 11-keto-β-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in... Agent: Fitch Even Tabin And Flannery

20090042833 - Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid: Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090042834 - Stabilized glycosaminoglycan preparations and related methods: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl... Agent: Stout, Uxa, Buyan & Mullins LLP

20090042835 - Compositions and methods for ameliorating hyperlipidemia: The invention provides compositions comprising a pharmaceutical compound having one or more Microsomal Triglyceride Transfer Protein (MTP) inhibitors that are covalently linked to one or more Liver Fatty Acid-Binding Protein (L-FABP) inhibitors. Also disclosed are methods for using the inventive pharmaceutical compositions in the treatment of hepatic steatosis and hyperlipidemia... Agent: Law Office Of Timothy M. Brown

20090042837 - Leptomycin compounds: e

20090042836 - Proteasome inhibitors: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20090042838 - Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin: The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin,... Agent: Hahn Loeser & Parks, LLP

20090042839 - Crystalline forms of ibandronate sodium: Provided are crystalline forms of ibandronate sodium, as well as processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20090042840 - Phospholipids for use in the treatment of an allergic inflammatory condition: A phospholipid comprising a diacyl-substituted phosphatidyl group and a pharmaceutical composition comprising such a phospholipid for use in treatment of an allergic inflammatory condition and a method for the treatment of an allergic inflammatory condition. The phospholipid is particularly a mixture of phospholipids known as pumactant.... Agent: Nixon & Vanderhye, PC

20090042841 - Novel heterocyclic derivatives as m-glu5 antagonists: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine... Agent: Darby & Darby P.C.

20090042842 - Analogues of cilostazol: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090042844 - 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations... Agent: Ostrolenk Faber Gerb & Soffen

20090042843 - Inhalation device containing plural doses of a pharmaceutical composition: The invention relates to an inhalation device comprising plural of doses of a pharmaceutical composition in powder form, wherein the pharmaceutical composition comprises one or more, preferably one, anticholinergic, optionally in combination with a pharmaceutically acceptable excipient.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090042845 - Suppression and prevention of tumors: Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or... Agent: Robert B. Aylor

20090042846 - Topical delivery system for phytosterols: m

20090042847 - 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations: Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxy-geldanamycin (17-AAG).... Agent: Fox Rothschild LLP Bristol-myers Squibb

20090042850 - Compositions and methods for cytoprotection: The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090042848 - Copper complexes: There are described mononuclear copper complexes having anti-inflammatory activity. The complexes include copper complexes of indomethacin. There are also provided methods for the prophylaxis or treatment of inflammation comprising administering such complexes to a mammalian subject.... Agent: Fulbright & Jaworski, LLP

20090042849 - Phosphorylation of 5-lipoxygenase at ser523 and uses thereof: The present invention provides novel mechanisms that regulate the production of anti-inflammatory and pro-inflammatory mediators generated by 5-lipoxygenase. In this regard, the present invention establishes that phosphorylation of 5-Lipoxygenase by protein kinase A, has a crucial role in determining the end products of 5-Lipoxygenase. With translocation to the nucleus, potent... Agent: Benjamin Aaron Adler Adler & Associates

20090042851 - Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors: e

20090042853 - Penem prodrugs:

20090042855 - Benzamide mglur5 positive allosteric modulators and methods of making and using same: In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N1-phenylterephthalamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090042854 - Hexahydro-3h-pyrrolizin-3-ones useful as tachykinin receptor antagonists: The present invention is directed to certain hexahydrpyrrolidinone compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20090042852 - Novel pyridine compounds: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20090042856 - Pyridazinone derivatives used for the treatment of pain: A pyridazinone derivative compound shown by the following formula (I): wherein R1 is selected from hydrogen, etc.; R2 is selected from substituted or unsubstituted aryl, etc.; R3 is hydrogen, etc.; p is 0, 1 or 2; R4 and R5, are each hydrogen, etc.; R6 and R7, are taken together to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090042857 - Novel pharmaceutical: p

20090042858 - Lactam containing hcv inhibitors: The present invention discloses novel methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including novel oxoazepanylacetamide derivatives useful for viral inhibition.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090042859 - Spiro-condensed indoline derivatives as pesticides: The use of a compound of formula I, wherein Y is a single bond, C═O, C═S or S(O)m where m is 0, 1 or 2; R′, R2, R3, R4, R8 and Ra are specified organic groups and p is 0, 1, 2, 3, 4, 5 or 6; q is 0,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090042860 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090042861 - Prophylactic or therapeutic agent for depression or anxiety disorder: The present invention provides a prophylactic or therapeutic agent for depression or anxiety disorders, comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.... Agent: Edwards Angell Palmer & Dodge LLP

20090042862 - Novel compounds: The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090042863 - Therapeutic agent for diabetes: e

20090042864 - Pyrazole compounds:

20090042865 - Dna-pk inhibitors: wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X is... Agent: Michael Best & Friedrich LLP

20090042866 - Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.... Agent: Hoffmann & Baron, LLP

20090042867 - Compounds for the treatment of alzheimer's disease: e

20090042868 - Indoleamine 2,3-dioxygenase (ido) inhibitors: Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell... Agent: Christie, Parker & Hale, LLP

20090042869 - Signal-dependent splicing of tissue factor pre-mrna in platelet cells: The invention relates to therapeutic target recognition, development, and validation of a compound capable of directly or indirectly modulating TF pre-mRNA splicing in a platelet cell and the use of a platelet TF pre-mRNA splicing modulator for the treatment of a subject suffering from, or thought to be suffering from,... Agent: Morriss Obryant Compagni, P.C.

20090042870 - Antimicrobial composition: e

20090042871 - Tricyclic delta-opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20090042872 - Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same: Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment... Agent: The Nath Law Group

20090042873 - Tricyclic n-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use: s

20090042874 - Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans: that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder,... Agent: Pepper Hamilton LLP/wyeth

20090042875 - Substituted heterocyclic compounds and uses thereof: The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more substituted heterocyclic compounds. In particular, the invention relates to... Agent: Jones Day

20090042876 - Pyrroloquinoline derivatives and their use as protein kinases inhibitors: e

20090042877 - Bicyclic heteroaromatic derivatives: Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090042878 - Thienopyrimidylamines as modulators of the ep2 receptor: The present invention relates to thienopyrimidylamines of the general formula I, to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20090042880 - Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives: e

20090042879 - Phthalazinone derivatives and pharmaceutical compositions comprising the same: In the structural formula [1], the partial structure bridging the 6-position and the 7-position represents a single bond or a double bond; R1 and R2 are the same or different and each represents alkyl or the like; Y represents phenylene or the like; Z represents alkylene or the like; and... Agent: Darby & Darby P.C.

20090042881 - Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors:

20090042882 - Substituted acetamides as modulators of the ep2 receptor: The present invention relates to substituted acetamides of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20090042883 - Antitumor agent: e

20090042884 - Pharmaceutical compounds: wherein R1 to R4, X and Y are defined in the specification are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function... Agent: Nixon & Vanderhye, PC

20090042885 - 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient: (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal... Agent: Sughrue-265550

20090042886 - Benzamide inhibitors of the p2x7 receptor: h

20090042887 - Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents: The present invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on... Agent: Dykema Gossett PLLC

20090042888 - Prostaglandin endoperoxide h synthase biosynthesis inhibitors: which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of... Agent: Paul D. Yasger Abbott Laboratories

20090042889 - Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment: The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof,... Agent: Reinhart Boerner Van Deuren P.C.

20090042892 - Cetp inhibitors: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic... Agent: Merck And Co., Inc

20090042890 - Heteroaryl compounds, compositions thereof, and methods of treatment therewith: wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an... Agent: Jones Day

20090042893 - Kinase inhibitors, compositions comprising them, and methods of their use: Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use.... Agent: Lexicon Pharmaceuticals, Inc.

20090042891 - Pyrazine derivatives useful as adenosine receptor antagonists: or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090042895 - Antidepressant piperidine derivatives of heterocycle-fused benzodioxans: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity,... Agent: Woodcock Washburn LLP/wyeth

20090042894 - Novel species of acrocarpospora, a method of preparing iodinin, and the uses of iodinin: The present invention provides a novel species of Acrocarpospora gen. that is capable of producing iodinin. The invention also provides a method of preparing iodinin, and uses of iodinin in inducing cytotoxicity and treating cancers.... Agent: Ladas & Parry LLP

20090042896 - Pyrrolidine aryl-ether as nk3 receptor antagonists: R2, R3, R4, n, o, p, and q are as defined herein and to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090042897 - Chemical compounds: ,

20090042899 - Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase: Piperazinyl- or piperidinylamine-sulfamic acid amides and their use for the manufacture of a medicament in diseases mediated by the action of steroid sulfatase.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090042898 - Use of compounds active on the sigma receptor for the treatment of mecanical allodynia: The present invention refert to the use of compounds active on the sigma receptor for the treatment of mechanical allodynia.... Agent: Banner & Witcoff, Ltd.

20090042900 - 2,4-diaminoquinazolines for spinal muscular atrophy: e

20090042901 - Agent for prevention/therapy of disease caused by keratinocyte growth:

20090042903 - Piperazinyl-pyridine derivatives: wherein R1, R2, X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090042902 - Therapeutic agents useful for treating pain: wherein Ar, Ar1, Ar2, R3, R4, R5, R6, R13, m, t, and x are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Hydroxyiminopiperazine Compound”); compositions comprising an effective amount of a Hydroxyiminopiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to... Agent: Dechert LLP

20090042904 - Substituted phenly-piperazine compounds, their preparation and use in medicaments: The present invention relates to substituted phenyl-piperazine compounds of general formula (I), a process for their preparation, medicaments comprising said substituted phenyl-piperazine compounds as well as the use of said substituted phenyl-piperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090042905 - Triazole derivatives as ligands of g-protein coupled receptors: The present invention provides triazole derivatives according to formula (I) as ligands of G-protein coupled receptors (GPCR), which are useful for the study of and/or the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, which are mediated by GPCR.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090042906 - Methods for treating cancers associated with constitutive egfr signaling: Aspects of the invention relate to methods and compositions for treating cancers associated with constitutive EGFR signaling. Methods include inhibiting one or more components of the c-Met and/or Axl signaling pathways. Aspects of the invention also relate to methods for determining whether a subject is a candidate for treatment with... Agent: Wolf Greenfield & Sacks, P.C.

20090042907 - Bicyclic aromatic sulfinyl derivatives: p

20090042908 - Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation:

20090042911 - Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3, 5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular... Agent: Morgan Lewis & Bockius LLP

20090042909 - Method of treating dermatological disorders: A method of treating a dermatological disorder in a subject includes the step of administering a therapeutically effective amount of at least one PPARγ agonist or derivative thereof to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090042910 - Quinoline derivatives for treating cancer: or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use... Agent: Morgan Lewis & Bockius LLP

20090042912 - Diphenylimidazolyl compounds as inhibitors of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.... Agent: Wyeth Patent Law Group

20090042913 - Indolylalkylthienopyrimidylamines as modulators of the ep2 receptor: The present invention relates to indolylalkylthienopyrimidylamines of the general formula I, to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20090042914 - Delayed release formulations of 6-mercaptopurine: The present invention provides enterically coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an... Agent: Kenyon & Kenyon LLP

20090042915 - Preventive or therapeutic agent for herpesvirus-releated disease: [Means for Solving Problems] The present invention relates to an anti-herpesvirus agent characterized by combining a helicase-primase inhibitor with a polymerase inhibitor. By combining the polymerase inhibitor with the helicase-primase inhibitor having different functional mechanisms, the anti-herpesvirus agent of the present invention achieves an extremely superior anti-herpesvirus activity compared with... Agent: Sughrue-265550

20090042916 - [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto: and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing... Agent: Townsend And Townsend And Crew, LLP

20090042917 - Aminopyrimidine derivative and plant disease control agent for agricultural or horticultural use: wherein R is a C2-10 alkyl group; R1 and R2 are each independently a hydrogen atom or a substituent such as an optionally substituted C1-10 alkyl group; X is hydrogen or a substituent selected from a predefined substituent group; Y is a substituent selected from a predefined substituent group; and... Agent: Bacon & Thomas, PLLC

20090042920 - Carbonylamino-derivatives as novel inhibitors of histone deacetylase: e

20090042919 - Method for modulating gpr119 g protein-coupled receptor and selected compounds: A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090042918 - Pyridopyrimidinone inhibitors of pim-1 and/or pim-3: Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R1, R3, Q, X and R4 are as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090042921 - Spiroindoline derivatives having insecticidal properties: An insecticidal compound of formula (I), wherein Y is a single bond, C═O, C═S or S(O)m where m is 0, 1 or 2; R1, R2, R3, R4, R8 A1, A2, A3, A4, B1, B2, B3 and B4 are specified organic groups or salts or N-oxides thereof; compositions containing them and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090042922 - Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis: Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or auto-immune therapeutic abilities. In general, methods of synthesis disclosed herein allow for introduction of a variety of substituents at numerous positions as well as the facile introduction of a... Agent: Fulbright & Jaworski L.L.P.

20090042923 - Method of treating tumors with azaxanthones: The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymal nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.... Agent: Gibbons P.C.

20090042924 - Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics: e

20090042926 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090042925 - Oxime substituted imidazoquinolines: Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090042928 - Modulators of muscarinic receptors: The modulator compounds described herein modulate muscarinic receptors and are useful for treating muscarinic receptor mediated diseases.... Agent: Miller Canfield Paddock And Stone PLC

20090042927 - Salts, prodrugs and polymorphs of fab i inhibitors: In part, the present invention is directed to antibacterial compounds and salts thereof.... Agent: Goodwin Procter LLP Patent Administrator

20090042929 - 11-beta-hydroxysteroid dehydrogenase inhibitors: There is provided a compound having Formula (I) R1-Z-R2 wherein R1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group... Agent: Steptoe & Johnson LLP

20090042930 - Pharmaceutical compositions containing clopidogrel bisulfate: Provided is a pharmaceutical composition including clopidogrel bisulfate and a pregelatinized starch. The pharmaceutical composition in which the stability of clopidogrel bisulfate is significantly enhanced can be obtained by mixing clopidogrel bisulfate with the pregelatinized starch.... Agent: Cantor Colburn, LLP

20090042931 - Tricyclic angiotensin ii agonists: wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as... Agent: Nixon & Vanderhye, PC

20090042932 - Antimicrobial parenteral formulation: e

20090042933 - Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptor: A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R1 is a group chosen from —CH2OH and —NHC(O)H; R2 is a hydrogen atom or R1 together with R2 form the group —NH—C(O)—CH═CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090042935 - Novel iv formulation of tipifarnib: This invention concerns compositions of tipifarnib, mannitol, and hydroxypropyl-β-cyclodextrin and, suitable for intravenous (IV) administration. The invention further concerns the use of such formulation and processes for preparing such formulations and methods of treating by administering said formulations.... Agent: Philip S. Johnson Johnson & Johnson

20090042934 - Sulfonyl-quinoline derivatives: The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes and intermediates for their preparation, to pharmaceutical compositions containing these compounds and to their use in treatment and/or prevention... Agent: Fish & Richardson PC

20090042936 - Compositions and methods for treating or controlling anterior-segment inflammation: A composition for treating or controlling an inflammatory anterior-segment disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”). The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in the anterior portion of the eye... Agent: Bausch & Lomb Incorporated

20090042937 - Nitroxides for use in treating or preventing amyloid-related diseases: Phamaceutical compositions are provided that are useful in treating amyloid protein-related diseases such as Alzheimer's disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that downregulates one or more genes related to the amyloid-related disease. Methods are also provided for... Agent: Knobbe Martens Olson & Bear LLP

20090042938 - Chemical compounds: The use of a compound of formula (I), Y is a single bond, C═O, C═S or S(O)m where m is 0, 1 or 2; the ring (II) is a 6 membered aromatic ring or is a 5 or 6 membered heteroaromatic ring; Z and Z′ are ═C— or —N— provided... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090042939 - Methods and compositions using cholinesterase inhibitors: The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic... Agent: Venable LLP

20090042940 - Methods and compositions using cholinesterase inhibitors: The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic... Agent: Venable LLP

20090042941 - Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method... Agent: Goodwin Procter LLP Patent Administrator

20090042942 - Muscarinic receptor antagonists: The invention provides compounds of formula (I), wherein R1, R2, R3, R4, R5, n and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.... Agent: Fish & Richardson P.C.

20090042943 - Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors: wherein R1 and A are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2A receptors... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090042944 - Potassium channel inhibitors: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20090042945 - Benzo[d]isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands: The present invention relates to substituted benzo[d]isoxazol-3-yl-amine compounds, methods for their production, medicaments containing these compounds and the use of these compounds to produce medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20090042946 - Method and kit for controlling bleeding: Methods and kits for controlling bleeding from a disrupted blood vessel, wherein a vanilloid receptor agonist is administered to the site of the disruption of the blood vessel in a quantity sufficient to control the bleeding.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20090042947 - Pharmacologically active compounds containing sulfur: Disclosed herein is a method for the production of disulfide compounds of the formula (I) PAC-SA—SB—R* (I) wherein PAC-SA is a residue of a pharmaceutically active drug a metabolite thereof or a pharmaceutically acceptable salt thereof that is covalently bonded via the sulfur atom, SA of a reduced sulfhydryl, sulfinyl,... Agent: Senniger Powers LLP

20090042948 - Physiologically acceptable salts of 3--1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester: The invention relates to new, physiologically acceptable salts of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090042949 - Indoles useful in the treatment of inflammation: wherein X1, T, Y, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the... Agent: Morgan Lewis & Bockius LLP

20090042950 - Transdermal topical composition and its uses: At least one silicone is used to modify the release profile of the active compound(s) in a therapeutic composition for topical application the skin that also comprises at least one penetration enhancer and a fugitive solvent base.... Agent: Catalyst Law Group, Apc

20090042951 - Blood pressure reduction in salt-sensitive hypertension: This invention provides methods and compositions, most preferably pharmaceutical compositions, for treating salt-sensitive hypertension through the inhibition of certain enzymes in the beta-adrenergic pathway that are involved in the regulation of the secretion of water and sodium. These enzymes are cyclic nucleotide phosphodiesterases (PDE) that selectively hydrolyze the second messenger... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090042952 - Sustained release composition for oral administration of niacin: A sustained release composition for oral administration of niacin, comprising niacin; a carrier for sustained release composed of a hydrophilic polymer and a hydrophobic polymer; and a pharmaceutically acceptable additive, the hydrophilic polymer being a polyethylene oxide and a natural gum, is capable of maintaining a constant release rate of... Agent: Sughrue Mion, PLLC

20090042953 - Imidazo [2,1,-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Lowrie, Lando & Anastasi, LLP

20090042954 - 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor antagonists: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of... Agent: Merck And Co., Inc

20090042955 - Bicyclic sphingosine 1-phosphate analogs: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Iplm Group, P.A.

20090042956 - Compositions and methods of using (r)-pramipexole: Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.... Agent: Pepper Hamilton LLP

20090042958 - Composition and method for treating immune-mediated skin disorders: Liquid or semi-liquid pharmaceutical compositions for topically treating immune-mediated skin disorders such as psoriasis, eczema, acne, dermatitis, and skin cancer and methods of treating patients having such immune-mediated skin disorders using the compositions.... Agent: Butzel LongIPDocketing Dept

20090042959 - Compounds having immunomodulator activity: with the proviso that when X and Y are hydrogen, R1-5 cannot represent a 4-hydroxy or 4-alkoxy groups, are useful for the treatment of Tumor Necrosis Factor mediated immunopathological conditions as well as of diseases which may be treated or alleviated by inhibition of Interleukin-10 (IL-10).... Agent: Pepper Hamilton LLP

20090042957 - Substituted oxyarenes: t

20090042960 - 1-cycloalkyl-5-iodotetrazoles:

20090042961 - Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090042962 - Therapeutic agent for keratoconjunctival disorder: e

20090042963 - Triazole-based fungicidal mixtures:

20090042964 - Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as beta-secretase inhibitors:

20090042965 - Inhibitors for steroid response elements and related methods: The present invention relates to polyamides capable of inhibiting ARE-, GRE- and ERE-mediated gene regulation in cells. The invention also relates to methods to treat diseases related to ARE-, GRE- and ERE-mediated gene regulation.... Agent: Stahl Law Firm

20090042966 - Mitotic kinesin inhibitors: The present invention relates to fluorinated dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090042967 - Cyclic amine compounds: The present invention also relates to methods for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis in a mammal, which comprises administering an effective amount of the pharmaceutical agents of the present invention or a prodrug thereof; use of the pharmaceutical agents of the present... Agent: Edwards Angell Palmer & Dodge LLP

20090042968 - Therapeutic compositions for intranasal administration of ketorolac: Therapeutic compositions, particularly sprayable aqueous compositions, comprise ketorolac or a pharmaceutically acceptable salt, in combination with a local anesthetic, such as lidocaine hydrochloride. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation and have the benefit of reduced stinging and improved efficacy, compared... Agent: Foley & Lardner LLP

20090042970 - Methods and devices for desmopressin drug delivery: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable... Agent: Goodwin Procter LLP Patent Administrator

20090042969 - Use of specific trifluoromethyl ketones for preventing and treating pancreatitis: The present invention relates to the use of specific trifluoromethyl ketones for preventing and treating pancreatitis and, more particularly, chronic pancreatitis or chronically recurring pancreatitis.... Agent: Nixon & Vanderhye, PC

20090042971 - Method of using low-dose doxepin for the improvement of sleep: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).... Agent: Knobbe Martens Olson & Bear LLP

20090042972 - Methods of using low-dose doxepin for the improvement of sleep: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).... Agent: Knobbe Martens Olson & Bear LLP

20090042973 - Inhibitors of aspartyl protease: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and... Agent: Ropes & Gray LLP

20090042974 - Compositions and methods relating to extensible transgenic vector assembler, pestilence ridder, plus cannabinoid producer: It is the ambition and intention of authors that tactical usage of this broad-sweeping technique may rapidly and at low cost satisfy a global demand in what may be termed a “grass-roots” bio-engineering project worthy of the 3rd Millennium; bringing to fruition micro-mass-productivity. Should a clear error be found either... Agent: Mr. Anson Parker

20090042975 - Process for the production of botanic extracts: Disclosed is a process for the production of botanic extracts containing at least 15% by weight of oligomeric proanthocyanidins of the OPC A2 type, comprising: (a) subjecting shells of the fruit of Litchi sinensis to extraction with lower, optionally aqueous aliphatic alcohols; (b) subjecting the extracts to chromatographic separation; (c)... Agent: Fox Rothschild LLP

20090042976 - Antimicrobial therapy for bacterial infections: The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090042977 - Anticancer compound, intermediate therefor, and processes for producing these: e

20090042978 - Pharmaceutical compositions containing nitrovinylfuran derivatives for the treatment of leishmaniosis and trypanosomosis:

20090042979 - Novel statin pharmaceutical compositions and related methods of treatment: The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily... Agent: Ratnerprestia-j&j

20090042980 - Neuroprotective compositions and methods: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and... Agent: Biotechnology Law Group C/o Portfolioip

20090042981 - Novel derivatives of 3,3-diphenylpropylamines: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine,... Agent: Kenyon & Kenyon LLP

20090042982 - Method for treating neurological disorders using acetone derivatives: The present invention provides a method of treating neurological disorders, such as epilepsy, comprising administering an effect amount of an acetone derivative having the formula R1—C(X)—R2, to an animal in need thereof. Such acetone derivatives show higher anticonvulsant activity, higher potency and improved therapeutic indexes over acetone itself.... Agent: Bereskin And Parr

20090042983 - Use of l-carnitine for the treatment of cardiovascular diseases: The use of L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicine useful for reducing the number of deaths caused by acute myocardial infarction and for improving the short-and-long-term prognosis in the patients treated with it, in which L-carnitine is administered parenterally within... Agent: Nixon & Vanderhye, PC

20090042984 - Cool-pet system: Included is an invention that deals with animal and pet nuisance, behavior control, obedience training, urinary and potty training, and repellent/discouragement method where a solution having vinegar and flavors being dispensed from a spray bottle is found to be effective in stopping or discouraging dogs, birds or animals from being... Agent: Wpat, PC Intellectual Property Attorneys

20090042985 - Process for the preparation of fatty acids: process for the preparation of a material comprising conjugated isomers of a polyunsaturated fatty acid comprises: treating a first fatty acid mixture comprising saturated fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids in the presence of ethanol to form (i) a solid fraction and (ii) a liquid fraction comprising... Agent: Morgan Lewis & Bockius LLP

20090042986 - Cosmetic liquid: A lotion is, ordinarily, slightly acidic, and moreover has been provided in such three kinds as an acidic lotion, an alkaline lotion, and a neutral lotion. The slight acidic lotion is ordinarily applied as being adapted to pH of skin and not having a particular stimulus thereto. Most of the... Agent: Edwards Angell Palmer & Dodge LLP

20090042988 - Pharmaceutical compositions containing a meglitinide compound for preventing hepatic fibrosis: The present invention discloses pharmaceutical compositions for preventing, improving or treating hepatic fibrosis, hepatocellular degeneration or cirrhosis, which contain a meglitinide compound such as nateglinide.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090042987 - Treatment of neuropathic pain: A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain.... Agent: Bozicevic, Field & Francis LLP

20090042989 - Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery: The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDS) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the... Agent: Wilson Sonsini Goodrich & Rosati

20090042990 - Novel use of a nutraceutical compositions in animal feed: This invention relates to the novel use of a composition comprising benzoic acid or a derivative of benzoic. It has been found surprisingly that the long-term ingestion of benzoic acid by swine was followed by a significant increase of the bone resistance and mineralization. The benzoic acid or its derivative... Agent: Nixon & Vanderhye, PC

20090042991 - Methods of increasing natural killer cell activity for therapy: Methods of employing bis(thio-hydrazide amides) to increase NK cell activity in a subject in need thereof, e.g., a subject with an infection or an immunodeficiency, are provided such that the disorder is not cancer, a proliferative cell disorder, a non-infective heat shock protein 70 (Hsp70) responsive disorder, or a proteasome-inhibitor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090042992 - Polymorphs of suberoylanilide hydroxamic acid: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090042993 - Identification of novel post-translational protein modifications: Compositions and methods for post-translational modifications that include protein acetylation in the ER lumen and deacetylation in the Golgi apparatus are provided. The disclosed methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's.... Agent: Warf/bhgl

20090042994 - Pesticide phenyloxy substituted phenylamidine derivatives: The present invention relates to 2,5-di-substituted-4-phenyloxy-substituted-phenyl-amidine derivatives of formula (I) in which the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or damaging... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090042995 - Therapeutic formulation: A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals.... Agent: Butzel LongIPDocketing Dept

20090042996 - Mixed fluoroalkyl-alkyl surfactants: p

20090042997 - Fluoroalkyl acid amide surfactants:

  
02/05/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090036352 - Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof: Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.... Agent: Novartis Corporate Intellectual Property

20090036350 - Method for stabilisation of a protein solution by addition of hydroxyl radical quenchers and its sterilisation by ionising radiation: A method of sterilising a protein in an aqueous environment, comprises exposing to ionising radiation an aqueous composition comprising the protein with a protective compound or combination of protective compounds having the following characteristics: (i) a rate of reaction with hydroxyl radicals greater than 5×108 L mol−1 s−1; and (ii)... Agent: Elmore Patent Law Group, PC

20090036349 - Methods and compositions related to targeting wounds, regenerating tissue, and tumors: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090036351 - Use of a protein hydrolysate for enhancing activity of glucagon-like peptide-1: A protein hydrolysate having a degree of hydrolysis between 1 and 40% and containing between 1 and 70 wt. % of peptides having a molecular weight of less than 500 Da and less than 55 wt. % of peptides or proteins having a molecular weight of more than 5000 Da,... Agent: Foley And Lardner LLP Suite 500

20090036348 - Use of novel hnf4a target genes and their gene products: Dysfunction of HNF4α may lead to disease and an identification of genes targeted by this factor provides insights into mechanisms of disease. In accordance with the invention thirteen new HNF4α target genes were found (C20orf13, KIAA0774, EPS15R, PLCB1, UGTREL1, RSK4, PAK5, FMR2, NEB, NFYC, KCNQ4, PRPF3, TRPC1). These genes were... Agent: Buchanan Ingersoll & Rooney PC

20090036354 - Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof: The invention relates to a carrier for administering biologically active compounds comprising one or more C1-C4 alcohols, polyols and polymers thereof, water and one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof. The carrier may be used in administering biologically active compounds, in particular pharmaceuticals including... Agent: Michael Best & Friedrich LLP

20090036353 - Insulin derivatives conjugated with structurally well defined branched polymers: Insulin conjugated with structurally well defined, bifurcated and trifurcated polymers can be use by pulmonary delivery for systemic absorption through the lungs to reduce or eliminate the need for administering other insulins by injection.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090036355 - Antisense modulation of ptp1b expression: Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or de-laying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The... Agent: Mcdermott Will & Emery

20090036356 - Octanoic acid derivatives as dipeptidyl peptidase inhibitors: m

20090036357 - Azapeptide derivatives: This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090036360 - Medicament containing activated antithrombin iii: The invention concerns the use of antithrombin III with a modified conformation which is referred to as activated antithrombin III (IDAAT=immune defence activated antithrombin) as a medicament.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090036358 - Methods of preparing pharmaceutical compositions for treatment of factor vlll associated disorders and methods of use: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.... Agent: Connolly Bove Lodge & Hutz, LLP

20090036359 - Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses: Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.... Agent: Marshall & Melhorn, LLC

20090036361 - Use of blood coagulation factor xiii for treating hemophilia a: A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090036362 - Angiogenesis affecting polypeptides, proteins, and composition, and methods of use thereof: The present invention relates to polynucleotides and proteins associated with vasculogenesis- and angiogenesis-related disorders. The invention further relates to methods for the identification of compounds that modulate the expression of angiogenesis-related genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders. The... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090036369 - Anti-tumor agents comprising r-spondins: The present invention provides an anti-tumor agent comprising a human R-spondin including R-spondin1 (GIPF), R-spondin2, R-spondin3 or R-spondin4, or a fragment thereof which has human R-spondin activity as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20090036377 - Axmi-028 and axmi-029, a family of novel delta-endotoxin genes and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Alston & Bird LLP

20090036380 - Composition and method for brain tumor therapy: A method of treating a disease associated with abnormal apoptosis in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one agent capable of increasing and/or stabilizing an interaction between at least an active portion of TrkA and... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090036372 - Composition and use of phyto-percolate for treatment of disease: This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The invention further relates to the use of the phyto-percolate in a variety of disease states. The phyto-percolate is believed to contain an activity that induces the reduction of... Agent: Brown Rudnick LLP

20090036373 - Compositions useful for and methods of modulating angiogenesis: Compositions and methods for treating subjects with disorders characterized by aberrant vascular endothelial cell growth are provided. The compositions comprise agents that are combinations of a Wnt pathway stimulator component and a Tie2 pathway repressor component. Particularly useful Wnt pathway stimulators include, but are not limited to, Wnt7b-like molecules. Particularly... Agent: Taft, Stettinius & Hollister LLP

20090036375 - Dbc1, a novel native inhibitor of anti-aging protein sirt1: A novel complex is identified between the NAD-dependent deacetylase, SIRT1 and its novel inhibitor, DBC1. Provided herein are methods to identify a compound that inhibits the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability... Agent: Cooper & Dunham, LLP

20090036364 - Gip analog and hybrid polypeptides with selectable properties: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090036374 - Hepatocyte growth factor receptor splice variants and methods of using same: Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention, are... Agent: Fennemore Craig

20090036365 - Inhibitors of human plasmin derived from the kunitz domains: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.... Agent: Lowrie, Lando & Anastasi, LLP

20090036366 - Inhibitors of human plasmin derived from the kunitz domains: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.... Agent: Lowrie, Lando & Anastasi, LLP

20090036379 - Inhibitors of proteins from the rho-gef family: A method for screening peptides with an aptamer library for determining inhibitors of any one of the proteins from the Rho-GEFs family.... Agent: Young & Thompson

20090036370 - Leukocyte adhesion inhibitor-1 (lai-1): There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human chemokine beta-11 (Ck beta-11) polypeptide and a human leukocyte adhesion inhibitor-1 (LAI-1) polypeptide (previously termed chemokine α1 (CKα1 or cka-1), as well as Ck beta-11 and/or LAI-1 polypeptides themselves, as are vectors, host cells and... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090036367 - Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine: The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against... Agent: The Firm Of Hueschen And Sage

20090036363 - Peptides as cell penetrating carriers: e

20090036382 - Tgf-beta modulators and use thereof: The present invention relates to molecules preferably of polypeptide nature with negative regulatory activity on the amount or activity of TGF-β through direct interaction with pro-TGF-β, and containing as active region a cysteine-rich polypeptide sequence defined as “EMI domain”, or its subfragments, wherein said “EMI domain” has at least 25%... Agent: Clark & Elbing LLP

20090036368 - Therapeutic combination: A combination of component (i) which is HAMLET or a biologically active modification thereof, or a biologically active fragment of either of these, and component (ii) which is a histone deacetylase (HDAC) inhibitor. This combination shows synergistic effects in the treatment of for example proliferative diseases such as those which... Agent: Nixon & Vanderhye, PC

20090036376 - Treatment for anxiety: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.... Agent: Townsend And Townsend And Crew, LLP

20090036381 - Treatment of diabetes: Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090036378 - Use of factor viia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090036371 - Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.... Agent: Alcon

20090036383 - Compositions and methods for promoting lipid mobilization in humans: The invention provides methods of using polypeptide compounds based on the structures of insect peptides of the adipokinetic hormone family to mobilize lipids in humans. The compositions and methods described in the application are useful for modulating human body weight, such as inducing weight loss. The invention also includes screening... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090036384 - Increasing pregnancy rates: The invention relates to a stable formulation for controlling oestrus in a subject. The formulation comprises Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof, progesterone or an analogue thereof, and an acceptable carrier.... Agent: Wood, Herron & Evans, LLP

20090036385 - Hair care preparation: It is intended to provide a hair care preparation. The invention is directed to a hair care preparation (a hair regrowth agent, a hair restorer or an agent for preventing hair loss) comprising as an effective component, an enzymatic or hydrolytic degradation product of a nucleoprotein and/or DNA or RNA,... Agent: Oliff & Berridge, PLC

20090036386 - Heterobifunctional compounds for selectin inhibition: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise glycomimetics linked to a compound, for example a member of... Agent: Seed Intellectual Property Law Group PLLC

20090036387 - Novel chemical entities affecting neuroblastoma tumor-initiating cells: Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children... Agent: Jagtiani + Guttag

20090036388 - Compounds: The present invention relates to novel 2′-O-substituted 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A derivatives having antimalarial activity. More particularly, the invention relates to 2′-O-substituted-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A and 2′-O-substituted-3-O-decladinosyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A derivatives having antimalarial activity, to the intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090036389 - Polymeric micelle formulations of hydrophobic compounds and methods: Provided are cosolvent evaporation methods and compositions for improving the solubility of hydrophobic compounds, including therapeutic agents such as anticancer drugs, polyene antibiotics, antilipidemic agents, and hydrophobic compounds used in various industries, and/or for reducing the toxicity of certain hydrophobic therapeutic agents, especially polyene antibiotics, in particular, Amphotericin B (AmB),... Agent: Greenlee Winner And Sullivan P C

20090036390 - Compositions and methods for treating neoplastic diseases: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.... Agent: Knobbe Martens Olson & Bear LLP

20090036391 - Modulation of line-1 reverse transcriptase: A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of... Agent: Reed Smith LLP

20090036392 - Composition comprising biodegradable hydrating ceramics for controlled drug delivery: The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the... Agent: Thorpe North & Western, LLP.

20090036394 - Grp 146 receptor: We disclose GPR146 G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding GPR146 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090036398 - Human g-protein coupled receptor (hetgq23): Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090036395 - Rna interference suppression of neurodegenerative diseases and methods of use thereof: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.... Agent: Viksnins Harris & Padys Pllp

20090036397 - Rnai-related inhibition of tnfa signaling pathway for treatment of macular edema: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular... Agent: Alcon

20090036396 - Rnai-related inhibition of tnfalpha signaling pathway for treatment of ocular angiogenesis: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk... Agent: Alcon

20090036393 - Vesicular monoamine transporter gene therapy in parkinson's disease: The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed.... Agent: Barnes & Thornburg LLP

20090036399 - Nucleoside derivatives for treating hepatitis c virus infection: e

20090036413 - Compositions, uses, and method of making wound care products from naturally occurring food ingredients: Rationally designed wound care products made entirely of naturally occurring food ingredients that can be standardized and made available for the mass market using good manufacturing practice (GMP) guidelines, optionally, a safe food additive can be added. These products: are safe and effective; have an osmotic pressure compatible with optimal... Agent: Jackson Walker LLP

20090036414 - Mesalamine formulations: Disclosed are oral dosage forms comprising an effective amount of mesalamine, wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution... Agent: Cantor Colburn, LLP

20090036415 - Identification and treatment of estrogen responsive prostate tumors: The present invention is directed to specific chromosomal rearrangements that are associated with prostate tumors that respond to compounds acting at estrogen receptors. Patients having the TMPRSS2-ERG fusion, may be treated with agonists of the estrogen beta receptor or antagonists of the estrogen alpha receptor.... Agent: Law Office Of Michael A. Sanzo, LLC

20090036417 - Cochleates without metal cations as bridging agents: This invention provides a cochleate and nano-cochleate systems wherein the agents bridging lipid bilayer are organic multi-valent cations. This invention also provides a method for preparing the cochleate system comprising direct cochleation and hydrogel-isolated procedure. The preparation method comprises using the charge ration between the bridging agents and lipids to... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090036416 - Novel cxcr4 antagonist and use thereof: A novel non-peptide CXCR4 antagonist has a low molecular-weight and uses various aromatic compounds, each containing a dipicolylamine-zinc complex. This CXCR4 antagonist finds use, e.g., as an anti-HIV agent, a metastasis inhibitor for a malignant tumor, and a chronic rheumatoid arthritis treatment and/or prevention agent.... Agent: Fitch, Even, Tabin & Flannery

20090036418 - Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient: As described above, the pyridylpyridazine compounds according to the present invention and the transition metal complexes thereof have anticancer activity and can be easily prepared at low cost. Thus, these compounds are useful as anticancer agents against various cancers, including lung cancer, adenocarcinoma, skin cancer, colon cancer, uterine cancer and... Agent: Staas & Halsey LLP

20090036422 - Monoamide derivatives as orexin receptor antagonists:

20090036424 - Association between hla-drbi*07 allele and susceptibily to increased levels of alat following ximelagatran administration: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between HLA-DRB1*07 allele and susceptibility to increased levels of alanine aminotransferase... Agent: Astrazeneca R&d Boston

20090036423 - Immunosuppresant compounds and compositions: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.... Agent: Novartis Corporate Intellectual Property

20090036420 - Benzamide derivatives and their use for treating cns disorders: e

20090036419 - Compounds useful as raf kinase inhibitors: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.... Agent: Choate, Hall & Stewart LLP

20090036421 - Pyrrole derivative or salt thereof: [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the... Agent: Fitzpatrick Cella Harper & Scinto

20090036425 - Substituted bicyclolactam compounds: e

20090036426 - Cb1 antagonists and inverse agonists: The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention conjointly with zonisamide, naltrexone, or a pharmaceutically acceptable salt thereof. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention conjointly... Agent: Ropes & Gray LLP

20090036434 - Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto: The present invention relates to certain substituted aryl and heteroaryl derivative of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.... Agent: Fish & Richardson P.C.

20090036437 - Pharmaceutical composition comprising phenoxazinium compound as an active ingredient: The purpose of the present invention is therefore to provide a pharmaceutical composition, especially that for the treatment and/or prevention of parasitic infection by protozoa, which has a high therapeutic effect and selective toxicity or a life-prolongation effect for the parasitic infection by protozoa. The present invention is therefore related... Agent: Dla Piper LLP (us) Attn: Patent Group

20090036438 - Five-membered heterocycles useful as serine protease inhibitors: or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation... Agent: Louis J. Wille Bristol-myers Squibb Company

20090036439 - 3-aryl-4-hydroxyfuranone compounds and the human and animal health use thereof: The present invention provides a compound of formula I and the use thereof for the inhibition of bacterial cell wall biosynthesis and for the therapeutic treatment of bacterial infection or disease in a patient in need thereof. The present invention also provides the use of the formula I compound for... Agent: Wyeth Patent Law Group

20090036440 - Novel pyrimidine derivatives - 816: where A1, A2 A3, R1, n, R2, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the... Agent: Morgan Lewis & Bockius LLP

20090036441 - Indole derivatives with antitumor activity: 3H-Benzo[e]indol-4,5-dione derivatives with antitumor activity, the processes for the preparation thereof and pharmaceutical compositions containing them.... Agent: Seed Intellectual Property Law Group PLLC

20090036442 - N-aroyl cyclic amine derivatives as orexin receptor antagonists: -

20090036444 - 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory... Agent: Leydig Voit & Mayer, Ltd

20090036443 - Thienopyrroles as antiviral agents: The present invention relates to thienopyrrole compounds of formula (I); wherein A, B, Y, Ar, n, Z and X1 are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.... Agent: Merck And Co., Inc

20090036445 - Kinase inhibitors: The present invention provides kinase inhibitors of Formula I.... Agent: Eli Lilly And Company Attn: Robert D. Titus

20090036446 - Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090036447 - Compounds, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090036448 - Pyrimidine derivatives and methods of treatment related to the use thereof: which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental... Agent: Sughrue Mion, PLLC

20090036449 - Indazolesquaric acid derivatives as chk1, chk2 and sgk inhibitors: Novel squaric acid compounds of the formula (I), in which R, R1, R2, R2′, R2″, R3, B, B′ and X have the meanings indicated in Claim 1, are inhibitors of CHK1 CHK2 and SGK kinases and can be used for the treatment of diseases and complaints such as cancer, diabetes,... Agent: Millen, White, Zelano & Branigan, P.C.

20090036450 - Pyrazole compounds and use thereof: v

20090036451 - Chemical inducers of neurogenesis: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in... Agent: Fulbright & Jaworski L.L.P.

20090036452 - Taar1 ligands: e

20090036454 - Compounds and uses thereof:

20090036453 - Pyrrolopyridazinone compound:

20090036456 - 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20090036455 - Arylpiperazine derivative and use thereof as 5-ht1a receptor ligands: Novel substituted arylpiperazine derivatives with activity as 5-hydroxytryptamine 1A (5-HT1A) receptor subtype ligands, to their stereochemical isomers, methods of their preparation, and to their use and to pharmaceutical compositions containing them for the treatment of Parkinson disease, cerebral damage by thromboembolic ictus, craneoencephalic traumatisms, depression, migraine, pain, psychosis, anxiety disorders,... Agent: Harness, Dickey, & Pierce, P.l.c

20090036457 - Utilities of olefin derivatives: in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ2-, —CY2═CZ2-, —CY2Y3—CHZ2-, —S—, —O—, or the like; Y1, Y2, Y3, Z1 and Z2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090036458 - Endoparasiticidal topical compositions:

20090036459 - Melanocortin type 4 receptor agonist piperidinoylpyrrolidines:

20090036460 - Crystalline pyridazine compound:

20090036461 - Use of azabicyclo hexane derivatives: in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090036462 - Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones:

20090036463 - Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase:

20090036464 - Treatment of posterior capsule opacification: This invention relates to a method of testing agents, such as sigma ligands for their potential use in treating posterior capsule opacification (PCO). The present invention also relates to the use of sigma ligands, such as sigma-1 antagonists in the manufacture of a medicament for preventing posterior capsule opacification (PCO),... Agent: Myers Bigel Sibley & Sajovec

20090036469 - 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists: wherein R1 and R2 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder by administering to said patient a pharmaceutically... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090036470 - Paliperidone derivatives: e

20090036471 - Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors:

20090036472 - Azabicyclo derivatives as anti-inflammatory agents: The present invention relates to novel azabicyclo derivatives of Formula (I) as anti-inflammatory agents which are useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and... Agent: Ranbaxy Inc.

20090036479 - Method of inhibiting choroidal neovascuarization: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.... Agent: Knobbe Martens Olson & Bear LLP

20090036480 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is... Agent: Morgan & Finnegan, L.L.P.

20090036481 - Novel azaindole inhibitors of mtp and apob: The present invention relates to 7-azaindole-based compounds, to processes for the preparation thereof, to pharmaceutical compositions comprising them, and to the use thereof in the preparation of medicaments that are useful as inhibitors of MTP and of ApoB secretion.... Agent: Millen, White, Zelano & Branigan, P.C.

20090036482 - Imidazopyridine-derivatives as inductible no-synthase inhibitors: e

20090036483 - Quinolinone compounds as 5-ht4 receptor agonists: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20090036484 - Use of unsaturated quionoline or naphtalene derivatives as medicaments: A compound of formula (I): (I), or a pharmaceutically acceptable salt thereof; for use as a medicament (for example modulating the glucocorticoid receptor in a warm blooded animal), and pharmaceutical compositions comprising such compounds.... Agent: Fish & Richardson P.C.

20090036485 - Quinoline derivatives: The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their... Agent: Morgan Lewis & Bockius LLP

20090036486 - Composition: The invention relates to the use of 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one for preparing a medicament intended to prevent or treat inflammatory disorders.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090036487 - Combinations: The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred AChE inhibitors are donepezil (Aricept®), tacrine (Cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine... Agent: Pfizer Inc.

20090036488 - Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia: The present invention provides a therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia. This therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia includes a drug that amplifies serotonin signals as an active component. This therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia includes a... Agent: Hoffmann & Baron, LLP

20090036512 - Fungicidal active compound combination: Active compound combinations comprising an oxime ether derivative of the formula (I) and captan and their use as fungicides are described.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090036513 - Antiviral drugs for treatment of arenavirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090036515 - Method for treating colonic viscerosensitivity and spasticity: There is provided a method of treating colonic viscerosensitivity and spasticity induced by a colonic examination chosen from colonic endoscopy and of barium/air contrast colonic radiography and virtual colonoscopy. The method comprises prescribing and/or administering to a patient in need thereof a pharmaceutically effective oral, sub-lingual, nasal or transdermic dose... Agent: Bereskin And Parr

20090036514 - Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090036516 - Compounds for treating metabolic syndrome: e

20090036517 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090036518 - Pharmaceutical composition containing flavonoids: A pharmaceutical composition is provided, where the pharmaceutical composition contains formula (I), (II), or (III) flavonoids which possess (PDE4), as a main ingredient. Especially, this composition has a binding affinity of high affinity rolipram binding sites (HARBS) of a PDE4 lower than a binding affinity of low affinity rolipram binding... Agent: Volpe And Koenig, P.C.

20090036519 - Peroxisome proliferator activated receptor ligand and process for producing the same: The present invention relates to a peroxisome proliferator-activated receptor ligand which comprises a prenylflavonoid, a chalcone derivative exclusive of prenylflavonoids, a flavonol derivative exclusive of prenylflavonoids, and a salt, a glycoside and/or an esterified substance thereof acceptable as a pharmaceutical preparation or a food or a beverage; a composition containing... Agent: Kenyon & Kenyon LLP

20090036520 - Combinations of vasoprotective agents and formulations containing them: Combinations of vasoprotective agents useful for the prevention and the treatment of vascular injuries induced by an excess of plasma lipids comprising polycosanols, tocotriends and/or lycopene, procyanidole oligomers and vegetable oil rich in insaturated fatty acids.... Agent: Young & Thompson

20090036521 - Process for production of optically active amine derivatives: An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the... Agent: Edwards Angell Palmer & Dodge LLP

20090036522 - Tablet containing hardly soluble active ingredient: A tablet showing regulated variation in dissolution from lot to lot which contains from about 3 to about 50% by weight (w/w), based on the whole tablet, of (S)—N—[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, magnesium stearate and hydroxypropylcellulose having a viscosity of about 1 to about 4 mPa·s.... Agent: Edwards Angell Palmer & Dodge LLP

20090036523 - Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same: Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.... Agent: Mayer Brown LLP

20090036524 - Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of nf-kappab: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-KB for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-KB inhibitor. The present invention also relates to compounds and methods useful to inhibit... Agent: Passe' Intellectual Property, LLC

20090036525 - Non-natural amino acid derivatives: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 and R3 are independently hydrogen, or a group —C(═O)R6 or —C(═O)OR6 wherein R6 is C1-C6 alkyl, or a group —CH2Q wherein Q is an optionally substituted monocyclic cycloalkyl or heterocyclyl ring of 3 to 6 ring atoms; R7 is (i)... Agent: Banner & Witcoff, Ltd.

20090036533 - Antibacterial agent comprising 7, 10-dihydroxy-8(e)-octadecenoic acid: The present invention relates to an antibacterial agent containing 7,10-dihydroxy-8(E)-octadecenoic acid (referred as DOD) as an active ingredient. DOD produced by the method of the present invention can be effectively used as an antibacterial agent because it has a wide spectrum of antibacterial activity against various microorganisms.... Agent: Lucas & Mercanti, LLP

20090036532 - Dha enrichment process: The present invention relates to a continuous process of DHA enrichment of a solution of fatty acids or derivatives thereof comprising less than 50% of DHA relative to the total fatty acids of the solution or to derivatives thereof, wherein the process comprises the steps of (a) simultaneous countercurrent injection,... Agent: Birch Stewart Kolasch & Birch

20090036531 - Method for treatment of onychomycosis: Onychomycosis is treated by grinding the infected portion of a nail down to a level where the nail is not infected and applying a coating of a cyanoacrylate ester to the ground portion which cures to a hard layer. The hard layer can be successively ground and coated with successive... Agent: Ralph D Chabot

20090036534 - Method of synthesizing s-allyl-cysteine analogues and their therapeutic application in treating myocardial infarction: A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and... Agent: Yuan Qing Jiang

20090036536 - Biphenyl compound selective agonists of gamma rar receptors: p

20090036535 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20090036537 - Aromatic triamide-lanthanide complexes: The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands... Agent: Morgan, Lewis & Bockius LLP (sf)

20090036538 - Treatment methods using triaryl methane compounds: The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for... Agent: Townsend And Townsend And Crew, LLP

20090036539 - Stable hyperbaric composition comprising prilocaine hcl, use of said new composition for intrathecal anaethesia, and method for manufacturing said composition: The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15° C.-27° C.). The present invention also concerns a method for manufacturing said compositions.... Agent: Squire, Sanders & Dempsey L.L.P.

20090036540 - Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction: A method is provided for the treatment of a condition mediated by raf kinase, which includes administering a guanylhydrazone to a subject in need thereof. A method is also provided, which includes modulating or inhibiting signal transduction in a c-raf pathway with at least one guanylhydrazone. Another method is provided,... Agent: Law Office Of John K. Pike, PLLC

20090036541 - Applicator and chemical combination for better topical anesthesia: One embodiment of a thin plastic applicator (1) containing a thinner plastic bubble (2) adhering to the inner surface (3) and containing a solution of dimethyl sulfoxide with one or more local anesthetic agent. A thick plastic rib (4) provides reinforcement, separating two textured sides (5) for ease of handling.... Agent: Donald David Mardis

20090036542 - Hydroquinone long-chain derivative and/or phenoxy long-chain derivative and pharmaceutical comprising same: e

20090036543 - Preservatives: The present invention relates to the use of compounds of the formula (1) wherein all substitutents have the meanings as defined in claim 1 as preservatives in personal care, pharmaceutical and household; the preservatives can also be used as in-can preservatives.... Agent: Joann Villamizar Patent Department

20090036544 - Methods and compositions for inhibiting the proliferation of prostate cancer cells: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of POH, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had... Agent: Fish & Richardson P.C.

20090036545 - Skin appearance through gene manipulation: The present invention relates to a method for treating, preventing and improving the condition and/or aesthetic appearance of aging skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, through meroterpene induced gene manipulation.... Agent: Edward K. Welch Ii Ip&l Solution

20090036546 - Medicinal oil compositions, preparations, and applications thereof: A medicinal white oil composition is prepared from an isomerized base oil. The isomerized base oil is filtered through a filter bed containing an acid activated clay having a surface area of at least 100 m2/g, for the base oil to be in compliant with at least one of European... Agent: Chevron Corporation

20090036547 - Insecticidal composition: The present invention relates to the use of a composition comprising cymene as a larvicide against mosquito larvae of a genus other than Culex and as an adulticide against mosquito adults.... Agent: Townsend And Townsend And Crew, LLP

20090036548 - Mascara and liquid eyeliner enhancer: A composition and method of use of a composition for enhancing the usability of eye cosmetics, including but not limited to mascara and liquid eyeliner. The composition and its formulation contains a liquid enhancer, such that a few drops of the liquid enhancer added to the mascara and/or liquid eyeliner... Agent: Mark Levy Hinman, Howard & Kattell, LLP

20090036549 - Substance-encapsulated carbon nanohorn complex and producing method thereof: A cap of polyamine molecules is provided on an aperture portion of carbon nanohorns having apertures formed by oxidation. The polyamine cap opens and closes according to the pH of the ambient environment, thereby controlling release of an encapsulation substance.... Agent: Scully Scott Murphy & Presser, PC

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.60543 seconds

PATENT INFO